Bio-Rad Laboratories Annual Report 2014

← All annual reports

FY2014 Annual Report · Bio-Rad Laboratories

Loading PDF…

B
B

i
i

o
o
-
-
R
R
a
a
d
d

L
L
a
a
b
b
o
o
r
r
a
a
t
t

o
o
r
r
i
i

e
e
s
s

A
n
n
u
a

R
e
p
o
r
t

2
0
1
4

Bio-Rad Laboratories
Bio-Rad Laboratories
Annual Report 2014
Annual Report 2014
Annual Report 2014

Letter to our
Shareholders
Shareholders

Once again, I am pleased to report another year of progress. Somewhat modest by historical

standards, sales increased 3.3% on a currency neutral basis to top $2.175 billion and net

income totaled nearly $89 million. While sales growth was modest, it does reflect a good

overall proxy of growth in the markets we serve.

Looking at our business around the

technologies. In our Life Science seg-

a company developing targeted

world, it is fair to say that the overall

ment, our customers have tradition-

applications in the ﬁ eld of diagnostics

picture is a conﬂ uence of pluses and

ally been focused on the study of

utilizing this droplet technology. In this

minuses. While European markets

genes and proteins. More recently,

case, a novel approach to DNA se-

for our Clinical Diagnostics products

additional attention is being given to

quence analysis is being developed,

continue to be challenging, we have

the study of cells, prompting us to

which promises to give diagnosti-

seen a nice rebound in our Life

continue down an investment path

cians a benchtop system capable

Science business. The reverse is true

to bring new, advanced tools to the

of sample-to-answer in under four

in Asia, where investments in advancing

market that will assist our customers

hours. Targeted areas for the system

healthcare systems outpaced growth

in the discovery process. We started

include assays for cancer, immune

in research spending. North American

modestly with the development of a

compatibility, and prenatal screening.

results were somewhat more balanced

cell counter. We expanded the port-

Especially intriguing is its potential in

by contrast. We feel that our worldwide

folio with the addition of a benchtop

the developing area of precision or

footprint is a tremendous advantage for

cell sorter that utilizes ﬂ ow cytometry,

personalized medicine. In addition,

us as we navigate the varied economic

and most recently we acquired a

we have been investing in three new

conditions around the globe.

broad portfolio of antibodies, which

diagnostic platforms supporting

Our proﬁ t, in contrast, is being driven

more by our internal investment in the

business than by the environment, al-

though it is fair to say that in the face

are a key reagent in cellular analy-

positions in some of our key markets,

sis, as well as other areas. This has

including diabetes, blood typing, and

opened up new opportunities for us

infectious disease.

in a large, growing market segment.

In 2014, we were also able to resolve

of economic austerity, customers are

Another important area of develop-

two long-standing corporate issues.

working hard to stretch every dollar,

ment for us has been the exciting

We reached a ﬁ nal settlement with

resulting in pricing pressures. The in-

new technology of Droplet Digital™

the U.S. government related to our

ternal investments we are working on

PCR. As we foray into this new

outstanding Foreign Corrupt Prac-

are substantial, but we feel they are

area, we are ﬁ nding an expanding

tices Act matter, an investigation we

necessary for our future. Key among

array of applications for discovery

initiated in 2009. We were also able

them is the investment we are making

based on the ability to encapsulate

to remediate the material weakness

in a global information management,

and manipulate DNA in thousands

over ﬁ nancial controls, which we have

or ERP system. We have grown up

of individual droplets. Although the

carried since 2013. While it is good

in a very decentralized environment.

technology has only been available

to have resolved those matters, we

Now, as we look to the future, we see

for a few years, there are already

are mindful that, as a complex and

advantages to a common globalized

over 200 peer-reviewed papers, a

expanding global enterprise, we must

system to help us better manage the

testament to the potential of this

be vigilant and continue to invest to

business and give us a tool to help

new discovery tool. As with most

improve our systems, practices, and

scale operations as we grow.

advances in science, the initial focus

procedures and train our person-

The other key area of investment for

us is new product areas and new

has been in the life science research

nel so that we ensure adherence to

market. In April of 2014, we were able

global standards and laws in those

to build on our expertise, acquiring

places where we conduct business.

BIO-RAD 2014 ANNUAL REPORT

We also took time in 2014 to look

at our organization in the context of

what we want to accomplish over the

next few years and for the future. The

operating structure we have had for

the last 10 plus years has taken us

through the $1 billion and $2 billion

milestones. Now, with a bigger goal,

we felt that functionally, the organi-

zation needed to evolve to be more

global; one that can better harness

the vast resources we have around

the world, driving more efﬁ ciency

and effectiveness for the business

and for our customers. In fact, we

have been moving in this direction

over the last few years as we have

globalized various functions. This

recent move, globalizing our supply

chain and sales organization, really

completes the transition. Concurrent

tive value of currencies around the

planned introduction of a new diabetes

with this change, it was important to

world. A strengthening dollar creates

platform to support this important

strengthen our management group

some currency headwinds for us

business area and introduction of the

with the establishment of the role of

given that a larger portion of our sales

IH-500, a mid-sized platform for blood

Chief Operating Ofﬁ cer. John Goetz,

are denominated in foreign currencies

typing. Also anticipated is U.S. approval

a long time and accomplished

while a larger portion of our costs are

for the IH-1000 automated blood typing

Bio-Rad manager, has ﬁ lled this

in U.S. dollars. We will have to see

system, our ﬂ agship platform for blood

position and will be a tremendous

how these currency changes play out

typing, which has been well accepted

asset to managing a more matrixed

in 2015. Our focus will be to manage

in the rest of the world. We are hoping it

operating environment. You will also

the challenges and take advantage

ﬁ nds a similarly important position in the

notice additional new management

of any opportunities that result from

U.S. market.

roles listed in the back of this report

this shift.

as we complete the transition.

Our investment spending should

see that the new organization success-

A ﬁ nal focus of ours for 2015 will be to

Looking forward to 2015, we expect

continue at a similar pace to 2014.

fully drives our programs for continued

similar economic and competi-

The expectation is that we will go

improvement.

tive challenges to those of 2014.

live with Deployment 2 of our ERP

Economically, we believe that 2015

program, covering the rest of North

will bring us continued weakness in

America and then begin to tackle

European markets, more modest

Europe. We will also continue to

growth in China, and stable research

invest in new technologies, which are

funding in most regions. There is

so vital for our future. At the same

We appreciate your interest in Bio-Rad.
We appreciate your interest in Bio-Rad.

some encouragement in the U.S. as

time, we will see the introduction of

Norman Schwartz

we may ﬁ nally be coming out of a

a number of new products and entry

PRESIDENT

six-year slump. In late 2014, we saw

into new markets to move the busi-

some signiﬁ cant changes in the rela-

ness forward. Key among them is the

BIO-RAD 2014 ANNUAL REPORT 1

The Business of Bio-Rad
Founded in 1952, Bio-Rad has a global team
of more than 7,600 employees and serves
life science research and clinical diagnostics
customers worldwide through its global network
of operations.

Throughout its existence, Bio-Rad has built long-lasting customer relationships
that advance the company’s research and development efforts and support the
introduction of innovative products and solutions that accelerate the discovery
process and improve healthcare.

L I F E S C I E N C E
L I F E S C I E N C E

CLINICAL DIAGNOSTICS

The Life Science Group develops, manufactures,

The Clinical Diagnostics Group develops,

and provides a wide range of laboratory instruments,

manufactures, sells, and supports a large portfolio of

apparatus, consumables, and reagents used for

products for medical screening and diagnostics.

research in the growing ﬁ elds of functional genomics,

Bio-Rad is a leading specialty diagnostics

proteomics, drug discovery and manufacture,

company and its products are recognized as the

cell biology, food safety, and science education.

gold standard for diabetes monitoring and quality

The group ranks among the top ﬁ ve life science

control systems. The group is also well known for

companies worldwide and is renown for quality,

its blood virus testing and detection, blood typing,

innovation, and a long-standing focus on the success

autoimmune and genetic disorders testing, and

of its customers. These products are based on

internet-based software products. Bio-Rad’s clinical

technologies used to separate, purify, identify, analyze,

diagnostics products incorporate a broad range of

and amplify biological materials such as proteins,

technologies used to detect, identify, and quantify

nucleic acids, cells, and bacteria. Technologies

substances in bodily ﬂ uids and tissues. The results

and applications include electrophoresis, imaging,

are used as aids to support medical diagnosis,

multiplex immunoassay, chromatography,

detection, evaluation, and the monitoring and

microbiology, bioinformatics, protein function analysis,

treatment of diseases and other medical conditions.

transfection, ﬂ ow cytometry, ampliﬁ cation, and real-

time and digital PCR. Bio-Rad products support

researchers in laboratories throughout the world.

PRODUCT AREAS

Gene Expression

Protein Puriﬁ cation

Protein Quantiﬁ cation

Cell Biology

Food Science

Science Education

2 BIO-RAD 2014 ANNUAL REPORT

PRODUCT AREAS

Diabetes

Hemoglobinopathies

Autoimmune Disease

Immunohematology

Infectious Disease

Quality Controls

2014 Financial Highlights
2014 Financial Highlights

F I V E - Y E A R R E C O R D

2010
2010
2010
2010

2011
2011
2011
2011

2012
2012
2012
2012

2013
2013
2013
2013

2014

(IN MILLIONS, EXCEPT FOR RETURN ON SALES
AND PER SHARE DATA)

Net Sales

Gross Proﬁ t

R & D Expense

$ 1,927.1
$ 1,927.1
$ 1,927.1
$ 1,927.1

$ 2,073.5
$ 2,073.5
$ 2,073.5
$ 2,073.5

$ 2,069.2
$ 2,069.2
$ 2,069.2
$ 2,069.2

$ 2,132.7
$ 2,132.7
$ 2,132.7
$ 2,132.7

$ 2,175.0

$ 1,091.8
$ 1,091.8
$ 1,091.8
$ 1,091.8

$ 1,178.8
$ 1,178.8
$ 1,178.8
$ 1,178.8

$ 1,155.2
$ 1,155.2
$ 1,155.2
$ 1,155.2

$ 1,178.5
$ 1,178.5
$ 1,178.5
$ 1,178.5

$ 1,178.5

$ 166.5
$ 166.5
$ 166.5
$ 166.5

$ 177.6
$ 177.6
$ 177.6
$ 177.6

$ 209.2
$ 209.2
$ 209.2
$ 209.2

$ 211.0
$ 211.0
$ 211.0
$ 211.0

$ 220.3

Net Income Attributable to Bio-Rad

$ 186.2
$ 186.2
$ 186.2
$ 186.2

$ 179.0
$ 179.0
$ 179.0
$ 179.0

$ 165.5
$ 165.5
$ 165.5
$ 165.5

$
$
$
$

77.8
77.8
77.8
77.8

88.8

Return On Sales

9.7%
9.7%
9.7%
9.7%

8.6%
8.6%
8.6%
8.6%

8.0%
8.0%
8.0%
8.0%

3.6%
3.6%
3.6%
3.6%

4.1%

Book Value Per Share

$ 55.25
$ 55.25
$ 55.25
$ 55.25

$ 61.98
$ 61.98
$ 61.98
$ 61.98

$ 70.75
$ 70.75
$ 70.75
$ 70.75

$ 75.99
$ 75.99
$ 75.99
$ 75.99

$ 75.17

Basic Earnings Per Share

$
$
$
$

6.73
6.73
6.73
6.73

$
$
$
$

6.39
6.39
6.39
6.39

$
$
$
$

5.85
5.85
5.85
5.85

$
$
$
$

2.72
2.72
2.72
2.72

3.08

Cash Flow From Operations*

$ 223.8
$ 223.8
$ 223.8
$ 223.8

$ 256.5
$ 256.5
$ 256.5
$ 256.5

$ 266.5
$ 266.5
$ 266.5
$ 266.5

$ 169.1
$ 169.1
$ 169.1
$ 169.1

$ 273.3

* Amounts include correction of immaterial errors and reclassiﬁ cation of certain amounts to be
consistent with the presentation in Form 10-K for the year ended December 31, 2014.

2014 SALES BY REGION

NET SALES

CASH FLOW

BASIC EARNINGS

2014 Sales by region

42%
EUROPE

39%
AMERICAS

19%
PACIFIC
RIM

NET SALES

( I N M I L L I O N S )

CASH FLOW

0
.
5
7
1
,
2
$

7
.
2
3
1
,
2
$

5
.
3
7
0
,
2
$

2
.
9
6
0
,
2
$

1
.
7
2
9
,

1
$

CASH FLOW
FROM OPERATIONS

CASH FLOW

BASIC EARNINGS
PER SHARE

BASIC EARNINGS

2014 Sales by region

( I N M I L L I O N S )

5
.
6
6
2
$

3
.
3
7
2
$

5
.
6
5
2
8 $
.
3
2
2
$

1
.
9
6
1
$

3
7
.
6
$

9
3
.
6
$

5
8
.
5
$

8
0
.
3
$

2
7
.
2
$

10 11 12 13 14

BIO-RAD 2014 ANNUAL REPORT 3

Bio-Rad
Sales
History

4 BIO-RAD 2014 ANNUAL REPORT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the year ended December 31, 2014
OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________________ to _________________________________

Commission file number 1-7928

BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

1000 Alfred Nobel Drive, Hercules, California
(Address of principal executive offices)

94-1381833
(I.R.S. Employer Identification No.)

94547
(Zip Code)

Registrant's telephone number, including area code

(510) 724-7000

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class
Class A Common Stock Par Value $0.0001 per share
Class B Common Stock Par Value $0.0001 per share

Name of Each Exchange on Which Registered
New York Stock Exchange
New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange

Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been

subject to such filing requirements for the past 90 days.

Yes

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data

File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period

that the registrant was required to submit and post such files).

Yes

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best
of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See
definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Non-accelerated file

(Do not check if a smaller reporting
company)

Smaller reporting company

Accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

As of June 30, 2014, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the Registrant's
Class A Common Stock held by non-affiliates was approximately $2,408,328,773 and the aggregate market value of the registrant's Class B Common Stock
held by non-affiliates was approximately $39,270,309.

As of February 17, 2015, there were 23,983,726 shares of Class A Common Stock and 5,117,908 shares of Class B Common Stock outstanding.

Documents Incorporated by Reference

Document

(1)

Definitive Proxy Statement to be mailed to stockholders in connection with the
registrant's 2015 Annual Meeting of Stockholders (specified portions)

Form 10-K Parts

III

BIO-RAD LABORATORIES, INC.

FORM 10-K DECEMBER 31, 2014

TABLE OF CONTENTS

Part I.

Item 1. Business

Item 1A. Risk Factors

Item 1B. Unresolved Staff Comments

Item 2. Properties

Item 3. Legal Proceedings

Item 4. Mine Safety Disclosures

Part II.

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities

Item 6. Selected Financial Data

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Item 8. Financial Statements and Supplementary Data

Item 9. Changes and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9A. Controls and Procedures

Item 9B. Other Information

Part III.

Item 10. Directors, Executive Officers and Corporate Governance

Item 11. Executive Compensation

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters

Item 13. Certain Relationships and Related Transactions, and Director Independence

Item 14. Principal Accountant Fees and Services

Part IV.

Item 15. Exhibits and Financial Statement Schedules

Signatures

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this Annual Report include forward-looking statements,
such as statements with respect to our future financial performance, operating results, plans and objectives that
involve risk and uncertainties. Forward-looking statements generally can be identified by the use of forward-
looking terminology, such as “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar
expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which
could cause actual results to vary materially from those expressed in or indicated by the forward-looking
statements. We have based these forward-looking statements on our current expectations and projections about
future events. However, actual results may differ materially from those currently anticipated depending on a variety
of risk factors including but not limited to those identified under “Item 1A, Risk Factors” of this Annual Report.
We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak
only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise, except as required by law.

PART I.

ITEM 1. BUSINESS

General

Founded in 1952 and incorporated in 1957, Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,”
“we,” “us,” and “our”) was initially engaged in the development and production of specialty chemicals used in
biochemical, pharmaceutical and other life science research applications. We entered the field of clinical
diagnostics with the development of our first test kit based on separation techniques and materials developed for life
science research. Through internal research and development efforts and acquisitions we have expanded into
various markets. Today, Bio-Rad manufactures and supplies the life science research, healthcare, analytical
chemistry and other markets with a broad range of products and systems used to separate complex chemical and
biological materials and to identify, analyze and purify their components.

As we broadened our product lines, we also expanded our geographical market. We have direct distribution
channels in over 35 countries outside the United States through subsidiaries whose focus is sales, customer service
and product distribution. In some regions, sales efforts are supplemented by distributors and agents.

Description of Business

Business Segments

Today, Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics. Both
segments operate worldwide. Our Life Science segment and our Clinical Diagnostics segment generated 33% and
66%, respectively, of our net sales for the year ended December 31, 2014. We generated approximately 32% of our
consolidated net sales for the year ended December 31, 2014 from U.S. sales and approximately 68% from sales in
our remaining worldwide markets.

For a description of business and financial information on industry and geographic segments, see Note 14 of Item 8
of Part II of this report.

Life Science Segment

Our Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological
questions. We are a leader in the life sciences market and develop, manufacture and market a range of more than
5,000 reagents, apparatus and laboratory instruments that serve a global customer base. Many of our products are
used in established research techniques, biopharmaceutical production processes and food testing regimes. These

techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and
bacteria within a laboratory or production setting. We focus on selected segments of the life sciences market in
proteomics (the study of proteins), genomics (the study of genes), biopharmaceutical production, cell biology and
food safety. We estimate that the worldwide market for products in these selected segments was approximately $8
billion. Our principal life science customers include universities and medical schools, industrial research
organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and
food testing laboratories.

Clinical Diagnostics Segment

Our Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test
kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Our products
currently address specific niches within the in vitro diagnostics (IVD) test market, and we seek to focus on the
higher margin, higher growth segments of this market.

We supply more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test
market. We estimate that the worldwide sales for products in the markets we serve were approximately $10 billion.
IVD tests are conducted outside the human body and are used to identify and measure substances in a patient’s
tissue, blood or urine. Our products consist of reagents, instruments and software, typically provided to our
customers as an integrated package to allow them to generate reproducible test results. Revenue in this business is
highly recurring, as laboratories typically standardize test methodologies, which are dependent on a particular
supplier’s equipment, reagents and consumable products. An installed base of diagnostic test systems therefore
typically creates an ongoing source of revenue through the sale of test kits for each sample analyzed on an installed
system. Our principal clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion
laboratories and physician office laboratories.

Raw Materials and Components

We utilize a wide variety of chemicals, biological materials, electronic components, machined metal parts, optical
parts, computing and peripheral devices. Most of these materials and components are available from numerous
sources, and generally we have not experienced difficulty in securing adequate supplies. However, in certain
instances we acquire components and materials from a sole supplier. Due to the regulatory environment in which
we operate, we may be unable to quickly establish additional or replacement sources for some components or
materials.

Patents, Trademarks and Licenses

We own numerous U.S. and international patents and trademarks. We also pay royalties on the sales of certain
products under several patent license agreements. We view these patents, trademarks and license agreements as
valuable assets; however, we believe that our ability to develop and manufacture our products depends primarily on
our knowledge, technology and special skills rather than our patent, trademark and licensing positions.

Seasonal Operations and Backlog

Our business is not inherently seasonal. However, the European custom of concentrating vacation during the
summer months usually tempers third quarter sales volume and operating income.

For the most part, we operate in markets characterized by short lead times and the absence of significant backlogs.
Management has concluded that backlog information is not material to our business as a whole.

Sales and Marketing

We conduct our worldwide operations through an extensive direct sales force and service network, employing
approximately 740 sales and service people around the world. Our sales force typically consists of experienced
industry practitioners with scientific training, and we maintain a separate specialist sales force for each of our
segments. We believe that this direct sales approach allows us to sell a broader range of our products and have
more direct contact with our customers; however, we also use distributors and agents, particularly in many of our
international markets.

Our customer base is broad and diversified. Our worldwide customer base includes (1) prominent university and
research institutions, providing us access to more than 150,000 scientists in the United States alone; (2) hospital,
public health and commercial laboratories; (3) other leading diagnostic manufacturers; and (4) leading companies in
the biotechnology, pharmaceutical, chemical and food industries. In 2014, no single customer accounted for more
than three percent of our total net sales. Our sales are affected by a number of external factors. For example, a
number of our customers, particularly in the Life Science segment, are substantially dependent on government
grants and research contracts for their funding. A significant reduction of government funding has in the past and
could in the future have a detrimental effect on the results of this segment.

Most of our international sales are generated by our wholly-owned subsidiaries and their branch offices. Certain of
these subsidiaries also have manufacturing facilities. Bio-Rad’s international operations are subject to certain risks
common to foreign operations in general, such as changes in governmental regulations, import restrictions and
foreign exchange fluctuations.

Competition

The markets served by our product groups are highly competitive. Our competitors range in size from start-ups to
large multinational corporations with significant resources and reach. We seek to compete primarily in market
segments where our products and technology offer customers specific advantages over the competition.

Because of the breadth of its product lines, our Life Science segment does not face the same competitors for all of
its products. Competitors in this market include GE Biosciences, Merck Millipore and Thermo Fisher Scientific.
We compete primarily based on meeting performance specifications and offering complete solutions.

Major competitors of our Clinical Diagnostics segment include Roche, Abbott Laboratories, Siemens, Danaher,
Thermo Fisher, Becton Dickinson, bioMérieux, Ortho Clinical Diagnostics, Tosoh, Immucor and DiaSorin.

Research and Development

We conduct extensive research and development activities in all areas of our business, employing approximately
735 people worldwide in these activities. Research and development has played a major role in Bio-Rad’s growth
and is expected to continue to do so in the future. Our research teams are continuously developing new products
and new applications for existing products. In our development of new products and applications, we interact with
scientific and medical professionals at universities, hospitals and medical schools, and within our industry. We
spent approximately $220.3 million, $211.0 million and $209.2 million on research and development activities in
2014, 2013 and 2012, respectively.

Regulatory Matters

The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising and
labeling of certain of our products (primarily diagnostic products) are subject to regulation in the United States by
the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) and in other
jurisdictions by state and foreign government authorities. FDA regulations require that some new products have
pre-marketing clearance or approval by the FDA and require certain products to be manufactured in accordance
with FDA’s “good manufacturing practice” regulations, to be extensively tested and to be properly labeled to

disclose test results and performance claims and limitations. After a product that is subject to FDA regulation is
placed on the market, numerous regulatory requirements apply, including, for example, the requirement that we
comply with recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and
reporting of corrections and removals. The FDA enforces these requirements by inspection and market
surveillance. The FDA has authority to take various administrative and legal actions against us for our, or our
products’, failure to comply with relevant legal or regulatory requirements, including issuing warning letters,
initiating product seizures, requesting or requiring product recalls or withdrawals, and other civil or criminal
sanctions, among other things.

We are also subject to additional healthcare regulation and enforcement by the federal government and by
authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without
limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician
sunshine laws and regulations. If our operations are found to be in violation of any of such laws or any other
governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and
criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in
federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate
our business and our financial results.

Sales of our products will depend, in part, on the extent to which our products or diagnostic tests using our products
will be covered by third-party payors, such as government health care programs, commercial insurance and
managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for certain
medical products and services. In addition, the U.S. government, state legislatures and foreign governments have
continued implementing cost containment programs, including price controls and restrictions on reimbursement.
Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions
with existing controls and measures, could further limit our net revenue and results. Decreases in third-party
reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not
cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our
sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be
adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and
services, which could result in reduced demand for our products or additional pricing pressures.

As a multinational manufacturer and distributor of sophisticated instrumentation, we must meet a wide array of
electromagnetic compatibility and safety compliance requirements to satisfy regulations in the United States, the
European Union and other jurisdictions.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such
activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal
practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations,
we are also subject to environmental laws and regulations that create liabilities and clean-up responsibility for
spills, disposals or other releases of hazardous substances into the environment as a result of our operations or
otherwise impacting real property that we own or operate. The environmental laws and regulations could also
subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our
operations or at any of our properties.

These regulatory requirements vary widely among countries.

Employees

At December 31, 2014, Bio-Rad had approximately 7,600 employees. Approximately eight percent of our
approximately 3,100 U.S. employees are covered by a collective bargaining agreement, which will expire on
November 8, 2016. Many of our non-U.S. full-time employees, especially in France, are covered by collective
bargaining agreements. We consider our employee relations in general to be good.

Available Information

Bio-Rad files annual, quarterly, and current reports, proxy statements, and other documents with the Securities and
Exchange Commission (SEC) under the Securities Exchange Act of 1934, as amended. The public may read and
copy any materials that we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington,
DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC
at 1-800-SEC-0330. Also, the SEC maintains an Internet website that contains reports, proxy and information
statements, and other information regarding issuers, including Bio-Rad, that file electronically with the SEC. The
public can obtain any documents that we file with the SEC at http://www.sec.gov.

Bio-Rad’s website address is www.bio-rad.com. We make available, free of charge through our website, our Form
10-Ks, 10-Qs and 8-Ks, and any amendments to these forms, as soon as reasonably practicable after filing with the
SEC. The information on our website is not part of this Annual Report on Form 10-K.

ITEM 1A. RISK FACTORS

In evaluating our business and whether to invest in any of our securities, you should carefully read the following
risk factors in addition to the other information contained in this Annual Report. We believe that any of the
following risks could have a material effect on our business, results of operations or financial condition, our
industry or the trading price of our common stock. We operate in a continually changing business environment,
and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor
can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and
uncertainties set forth below may adversely affect our business, results of operations, financial condition, our
industry or the trading price of our common stock.

Our settlement with government agencies in connection with violations by us of the U.S. Foreign Corrupt
Practices Act could have a material adverse effect on our business, results of operations and financial condition.

As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice
(DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC
(SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our
violations of the U.S. Foreign Corrupt Practices Act (FCPA). Under the terms of the NPA and the SEC Order, we
agreed to pay a financial penalty and certain amounts in disgorgement and interest as well as to compliance,
reporting and cooperation obligations to be performed for two years. For additional information regarding this
settlement and related legal proceedings, see Item 3 of this Annual Report.

We cannot be certain that our remediation efforts will be sufficient to comply with the terms of the NPA and the
SEC Order. Our failure to comply with the NPA and the SEC Order could result in future actions against us by the
DOJ and the SEC. In addition, whether by virtue of announcement of the NPA and the SEC Order or otherwise, we
may be subject to investigations by foreign governments or further claims by third parties arising from conduct
subject to the investigation or our other international operations. Many of our customers in our significant
international operations are government agencies or state-owned or state-controlled universities, hospitals and
laboratories. The announcement of the NPA and the SEC Order may harm our reputation with these customers,
which could materially adversely affect our business, results of operations and financial condition.

Our international operations expose us to additional costs and legal and regulatory risks, which could have a
material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 35 countries outside the
United States, and in 2014 our foreign subsidiaries generated 68% of our net sales. Compliance with complex
foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business.
These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements,
labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, export requirements, U.S.

laws such as the FCPA and other U.S. federal laws and regulations established by the office of Foreign Asset
Control, local laws such as the UK Bribery Act 2010 or other local laws which prohibit corrupt payments to
governmental officials or certain payments or remunerations to customers.

Given the high level of complexity of these laws, there is a risk that we may inadvertently breach some provisions,
for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain
formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these
risks and manage these challenges through policies, procedures and internal controls. However, we have a
dispersed international sales organization, and we use distributors and agents in many of our international
operations. This structure makes it more difficult for us to ensure that our international selling operations comply
with our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our
employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries,
implementation of compliance programs, and prohibitions on the conduct of our business. For example, and as
previously reported, in 2014 our selling subsidiary in China was subject to an administrative penalty and
disgorgement of profits of $0.3 million for providing free products pursuant to contractual obligations with
customers during 2012 and 2013, which was deemed to be in violation of China’s Anti-Unfair Competition Law.
Violations of laws and regulations could result in prohibitions on our ability to offer our products in one or more
countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to
attract and retain employees, or our business, results of operations and financial condition. See also our risk factor
regarding government regulations below.

The industries and market segments in which we operate are highly competitive, and we may not be able to
compete effectively.

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have
merged, and some of our competitors have greater financial resources than we do and are less leveraged than we
are, making them better equipped to license technologies and intellectual property from third parties or to fund
research and development, manufacturing and marketing efforts. For more information on our competitors, see
“Competition” in Item 1 of this Annual Report. Moreover, competitive and regulatory conditions in many markets
in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and
services resulting from inflation and other drivers of cost increases. Many public tenders have become more
competitive due to governments lengthening the commitments of their public tenders to multiple years, which
reduces the number of tenders in which we can participate annually. Because the value of these multiple-year
tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively
and/or pricing pressures resulting from competition could adversely affect our business, results of operations and
financial condition.

We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and
introduce new product lines and extensions that integrate technological advances. In particular, we may not be able
to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point-
of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop,
manufacture and market new product lines and extensions successfully and in a timely manner, our business, results
of operations and financial condition will be adversely affected. We have experienced product launch delays in the
past, and may do so in the future. We cannot assure you that our product and process development efforts will be
successful or that new products we introduce will achieve market acceptance. Failure to launch successful new
products or improvements to existing products may cause our products to become obsolete, which could harm our
business, results of operations and financial condition.

Our failure to establish and maintain effective internal control over financial reporting could result in material
misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to
lose confidence in our reported financial information, which in turn could cause the trading price of our
common stock to decline.

Maintaining effective internal control over financial reporting is necessary for us to produce reliable financial
statements. In connection with our assessment of the effectiveness of internal control over financial reporting and
the preparation of our financial statements for the year ended December 31, 2013, we identified a material
weakness in the design of monitoring controls over operations at certain of our locations both within the United
States and overseas, as well as a lack of documentation required to operate these controls appropriately. Although
we have remediated this material weakness as of December 31, 2014, we cannot assure you that additional material
weaknesses in our internal control over financial reporting will not be identified in the future. For example, we
previously identified different material weaknesses in internal controls at December 31, 2012 and December 31,
2010, both of which have been remediated.

Such material weaknesses have adversely affected us in the past and could affect us in the future, and the results of
our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our
internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to
maintain new and more precise monitoring controls and improved detection and communication of financial
misstatements across all levels of the organization could result in additional material weaknesses, result in material
misstatements in our financial statements and cause us to fail to meet our reporting obligations. This could cause us
to lose public confidence, and could cause the trading price of our common stock to decline. For further
information regarding our controls and procedures, see Item 9A of this Annual Report.

We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our
results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make
purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies
relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our
international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar
negatively impacts our consolidated net sales expressed in U.S. dollars. In 2014 our consolidated net sales grew by
3.3% compared to 2013 on a currency neutral basis; however, due to the strengthening of the U.S. dollar relative to
other currencies in which we sell products our consolidated net sales only grew by 2.0% as reported in U.S. dollars.
Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the
volatility of other currencies, such as the Swiss Franc and Russian Ruble, may negatively impact our operations
outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you
that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and
financial condition. For further information regarding our foreign exchange risk, see “Foreign currency exchange
gains and losses” in Item 7 and “Foreign Exchange Risk” in Item 7A of this Annual Report.

Recent changes to our organizational structure and executive management team could negatively impact our
business.

We recently made significant changes to our organizational structure. We functionalized our manufacturing and
selling organizations globally and separated them from our marketing and research and development organizations.
Specifically, we combined our international selling organization with our North American selling divisions into one
global selling group and consolidated our manufacturing divisions into one global manufacturing group. We also
created new management positions to head each of these groups. In addition, we recently appointed new executives
to head each of our Life Science and Clinical Diagnostics segments, and we appointed a Chief Operating Officer.
We also recently restructured our Life Science segment based on functional groups rather than product line
divisions. These changes may have unintended consequences, such as distraction of our management and

employees, business disruption, attrition of our workforce, inability to attract or retain key employees, and reduced
employee morale or productivity.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The
ERP is designed to efficiently maintain our books and records and provide information important to the operation of
our business to our management team. The ERP will continue to require significant investment of human and
financial resources. In implementing the ERP, we may experience significant delays, increased costs and other
difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely
affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or
otherwise operate our business. For example, we experienced system implementation issues in our Clinical
Diagnostics segment during our first deployment that impacted invoicing and caused an increase in accounts
receivable. While we have invested significant resources in planning, project management and training, additional
and significant implementation issues may arise. In addition, our efforts to centralize various business processes
and functions within our organization in connection with our ERP implementation may disrupt our operations and
negatively impact our business, results of operations and financial condition.

Breaches of our information systems could have material adverse effect on our business and results of
operations.

Through our sales and eCommerce channels, we collect and store confidential information that customers provide
to, among other things, purchase products or services, enroll in promotional programs and register on our Web site.
We also acquire and retain information about suppliers and employees in the normal course of business. We also
create and maintain proprietary information that is critical to our business, such as our product designs and
manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise
resource planning implementation and the centralization of our global information technology organization, we
could experience a significant data security breach. Computer hackers may attempt to penetrate our or our vendors’
information systems and, if successful, misappropriate confidential customer, supplier, employee or other business
information, such as our intellectual property. Third parties could also gain control of our systems and use them for
criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting
new customers, be exposed to claims from customers, financial institutions, payment card associations, employees
and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a
result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales
orders, particularly through our eCommerce channels, could also be disrupted. Any significant breakdown,
intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material
adverse effect on our business and results of operations. See also our risk factors regarding our ERP
implementation above and our information technology systems below.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure
agreements to protect our intellectual property rights and products. However, we cannot assure you that our
intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that
meaningful protection or adequate remedies will be available to us. For instance, unauthorized third parties have
attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as
proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally,
third parties have asserted patent, copyright and other intellectual property rights to technologies that are important
to us, and may do so in the future. If we are unable to license or otherwise access protected technology used in our
products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and
marketing such products. From time to time, we also must enforce our patents or other intellectual property rights
or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could
incur substantial costs, be forced to redesign our products, or be required to pay damages to an infringed party. Any
of the foregoing matters could adversely impact our business, results of operations and financial condition.

Global economic conditions could continue to adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. Further deterioration in the
global economic environment may result in decreased demand for our products, increased competition, downward
pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may
also adversely affect our suppliers, which could result in interruptions in supply in the future. We have also
experienced delays in collecting receivables in certain countries in Western Europe, and we may experience similar
delays in these and other countries or regions experiencing liquidity problems. As of December 31, 2014, we had
accounts receivable, net of allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of $45.4 million.
In addition, a slowing of growth in the Chinese economy and in emerging markets, especially those oil-producing
countries that have been affected by the recent decline in oil prices, could adversely affect our business, results of
operations or financial condition.

Reductions in government funding and the capital spending programs of our customers could have a material
adverse effect on our business, results of operations or financial condition.

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and
pharmaceutical, biotechnology and chemical companies. The capital spending programs of these institutions and
companies have a significant effect on the demand for our products. Such programs are based on a wide variety of
factors, including the resources available to make such purchases, the availability of funding from grants by
governments or government agencies, the spending priorities for various types of equipment and the policies
regarding capital expenditures during industry downturns or recessionary periods. If government funding to our
customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to
us, our business, results of operations or financial condition could be materially and adversely effected. For more
information on our customers, see “Sales and Marketing” in Item 1 of this Annual Report.

Changes in the healthcare industry could have an adverse effect on our business, results of operations and
financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs.
These changes include:

• The trend towards managed care, together with healthcare reform of the delivery system in the United

States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other
participants in the healthcare industry to reduce selling prices. Consolidation among healthcare providers
has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment
leverage. In particular, there has been a consolidation of blood transfusion centers, as well as an industry
decline in the number of blood transfusions. These industry trends and competitive forces place constraints
on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for
products we sell in clinical diagnostic markets.

• Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements
for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of
reimbursement available for clinical tests from third party payors. In the United States payment for many
diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical
Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers
for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in
establishing their reimbursement rates. Clinicians may decide not to order clinical diagnostic tests if third
party payments are inadequate, and we cannot predict whether third party payors will offer adequate
reimbursement for tests utilizing our products to make them commercially attractive. Recent legislation,
such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, have reduced

the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to
Medicare Act of 2014 will make significant changes to the way Medicare will pay for clinical laboratory
services, which will further reduce reimbursement rates.

• The PPACA has also imposed a 2.3% excise tax on the sales of certain medical devices in the U.S., which

we are required to pay on most of our United States Clinical Diagnostic sales.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures
such as those contained in the PPACA and the Protecting Access to Medicare Act of 2014, or in future legislation,
by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests,
our business, results of operations and financial condition could be adversely affected. If these changes in the
healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling,
marketing, distributing and servicing our products.

We are subject to substantial government regulation, and any changes in regulation or violations of regulations
by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject
to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign
counterparts. The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to
significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements
including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting
regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety
of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to
suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of
production, withdrawal of approvals or clearances already granted, and criminal prosecution. The FDA can also
require us to repair, replace or refund the cost of devices that we manufactured or distributed.

In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing
regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our
ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of
certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single
laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments
for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not
reviewed such tests for approval. However, the FDA has recently issued guidance that it will begin enforcing its
medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure
to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these
products and adversely affect our business operations and financial results. Additionally, the FDA and other
regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased
scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using
our products.

Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale
and use of our products. Such agencies may also impose new requirements that may require us to modify or re-
register products already on the market or otherwise impact our ability to market our products in those countries.
For example, Europe is currently making its regulations for product labeling stricter, Russia has recently enacted
more stringent medical product registration regulations, and we expect China, Brazil and India to impose more
regulations that impact our product registrations. Increasing protectionism in such countries also impedes our
ability to compete with local companies. For example, we may not be able to participate in certain public tenders in
Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing
capabilities. Specifically, a resolution passed by Russia in February 2015 prohibits the procurement of certain types
of medical devices by Russian state entities from foreign companies provided there are a sufficient number of

Russian manufacturers submitting tenders. Such regulations could adversely affect our business, results of
operations and financial condition.

We are also subject to government regulation of the use and handling of a number of materials and controlled
substances. The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting,
storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of
1970. Failure to comply with present or future laws and regulations could result in substantial liability to us,
suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us
to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our
company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies,
products and technologies. For information about our recent acquisitions, see "Overview" in Item 7 of this Annual
Report. In order to be successful in these activities, we must, among other things:

assimilate the operations and personnel of acquired companies;
retain acquired business customers;

•
•
• minimize potential disruption to our ongoing business;
retain key technical and management personnel;
•
integrate acquired companies into our strategic and financial plans;
•
accurately assess the value of target companies, products and technologies;
•
comply with new regulatory requirements;
•
•
harmonize standards, controls, procedures and policies;
• minimize the impact to our relationships with our employees and customers; and
•

assess, document and remediate any deficiencies in disclosure controls and procedures and internal control
over financial reporting.

The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our
financial statements. Completing any potential future acquisitions could cause significant diversion of our
management’s time and resources. If we acquire new companies, products or technologies, we may be required to
assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. We
cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection
with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and
financial condition.

Product quality and liability issues could harm our reputation and negatively impact our business, results of
operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering,
design and manufacturing processes, as well as defects in third-party components included in our products. Our
instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially
those affecting reagents or third-party components, is difficult. We may incur significant costs and expend
substantial time in researching and remediating such issues. Quality issues could also delay our launching of new
products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to
our products, could result in product recalls or product liability or other claims being brought against us. These
issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new
customers, which could negatively impact our business, results of operations and financial condition.

Lack of key personnel could hurt our business.

Our products are very technical in nature. In general, only highly qualified and well-trained scientists have the
necessary skills to develop, market and sell our products, and many of our manufacturing positions require very
specialized knowledge and skills. In addition, the global nature of our business also requires that we have
sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We
face intense competition for these professionals from our competitors, customers, marketing partners and other
companies throughout our industry. In particular, the job market in Northern California, where many of our
employees are located, has improved significantly. If we do not offer competitive compensation and benefits, we
may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly
run our business.

In some cases we rely on temporary personnel or consultants, and we may do so in the future. Such temporary
personnel or consultants may lack the knowledge and/or specific skills necessary for our business, require time to
train without benefiting us through extended employment and increase our costs. In addition, as noted above, our
strategic initiatives, such our internal restructuring and ERP implementation, may be burdensome and disruptive
and lead to employee dissatisfaction and attrition.

A reduction or interruption in the supply of components and raw materials could adversely affect our
manufacturing operations and related product sales.

The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components
and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire
our components and materials from many suppliers in various countries. We work closely with our suppliers to
ensure the continuity of supply but we cannot guarantee these efforts will always be successful. Further, while we
seek to diversify our sources of components and materials, in certain instances we acquire components and
materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be
unable to quickly establish additional or replacement sources for some components or materials. If our supply is
reduced or interrupted, and we are unable to develop alternative sources for such supply, our ability to manufacture
our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our
ability to sell our products.

If our information technology systems are disrupted, or if we fail to successfully implement, manage and
integrate our information technology and reporting systems, our business, results of operations and financial
condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT
systems could have a material adverse effect on our business, results of operations and financial condition. We
depend on our IT systems to process orders, manage inventory and collect accounts receivable. Our IT systems also
allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis,
maintain cost-effective operations and provide customer service. We cannot assure you that our contingency plans
will allow us to operate at our current level of efficiency.

Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and
analytical processes. We expect that we will need to continue to improve and further integrate our IT systems,
reporting systems and operating procedures by training and educating our employees with respect to these
improvements and integrations on an ongoing basis in order to effectively run our business. We may suffer
interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to
successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely
affect our business, results of operations and financial condition. See also our risk factors regarding our ERP
implementation and data security above.

Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or
disruption to us and our employees, facilities, information systems, security systems, vendors and customers,
which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France,
Switzerland, Germany and Singapore. In particular, the western United States has experienced a number of
earthquakes, wildfires, floods, landslides and other natural disasters in recent years. These occurrences could
damage or destroy our facilities which may result in interruptions to our business and losses that exceed our
insurance coverage. In addition, strikes or other labor unrest at any of our sites or surrounding areas could cause
disruption to our business. For example, we have experienced some delays in our supply of raw materials and
shipments of products to customers due to recent labor unrest at the seaports in the western United States. If the
situation continues or worsens, we may experience further disruption of our business or increased costs as we rely
more on air freight. Acts of terrorism, bioterrorism, violence or war could also affect the markets in which we
operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as
in Southeast Asia, the Middle East and Eastern Europe. In particular, the recent political turmoil in Ukraine, along
with the response of the Russian and U.S. governments to this situation, has the potential to impact our operations
in Russia. Any of these events could adversely affect our business, results of operations and financial condition.

Environmental, health and safety regulations and enforcement proceedings may negatively impact our business,
results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such
activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal
practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations,
we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills,
disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise
impacting real property that we own or operate. The environmental laws and regulations also subject us to claims
by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any
of our properties. We must also comply with various health and safety regulations in the United States and abroad
in connection with our operations.

We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and
possible new statutory enactments, and these expenditures may be significant. We have incurred, and may in the
future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other
releases of hazardous substances into the environment at sites where we have operated, or at off-site locations
where we have sent hazardous substances for disposal. We cannot assure you, however, that such matters or any
future obligations to comply with environmental or health and safety laws and regulations will not adversely affect
our business, results of operations or financial condition.

We may be subject to additional tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We calculate our provision for
income taxes in each jurisdiction in which we operate. Significant judgment is required in determining our
worldwide provision for income taxes and in the ordinary course of business, there are many tax positions taken
where the ultimate resolution is uncertain. We are subject to the examination of our tax positions in the United
States and many other foreign jurisdictions. Taxing authorities have disagreed with our judgment in the past and
may disagree with positions we take in the future resulting in assessments of additional taxes. Economic and
political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult.
For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid
debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the
likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income
taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related
litigation could be materially different from our historical income tax provisions and accruals. The results of an

audit or litigation could have a material effect on our consolidated financial statements in the period or periods for
which that determination is made. Changes in factors outside of our control, such as changes in tax laws or rates,
changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect
our financial position and results of operations.

Our debt may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of December 31, 2014, we had
approximately $436.0 million of outstanding indebtedness. In addition, we have a revolving credit facility that
provides for up to $200.0 million, $5.0 million of which has been utilized for domestic standby letters of credit.
Our incurrence of substantial amounts of debt may have important consequences. For instance, it could:

• make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding

•

•
•

debt;
require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and
principal due under our debt, which will reduce funds available for other business purposes;
increase our vulnerability to general adverse economic and industry conditions;
limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we
operate;
place us at a competitive disadvantage compared with some of our competitors that have less debt; and
limit our ability to obtain additional financing required to fund working capital and capital expenditures and
for other general corporate purposes.

Our existing credit facility and the terms of our other debt instruments, including agreements we may enter in the
future, contain or will contain covenants imposing significant restrictions on our business. These restrictions may
affect our ability to operate our business and may limit our ability to take advantage of potential business
opportunities as they arise. These covenants place restrictions on our ability to, among other things: incur
additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter
into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or
pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires
that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum
consolidated interest coverage ratio test.

Our ability to comply with these covenants may be affected by events beyond our control, including prevailing
economic, financial and industry conditions. The breach of any of these restrictions could result in a default. An
event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from
them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other
indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal
amount of our outstanding notes or may cause the future subsidiary guarantors, if any, to be unable to make
payments under the guarantees.

We are subject to healthcare fraud and abuse laws and regulations and could face substantial penalties if we are
unable to fully comply with such laws.

We are subject to healthcare fraud and abuse regulation and enforcement by both the U.S. federal government and
the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations
include, for example:

•

the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from
soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce
either the referral of an individual for, or the purchase order or recommendation of, any item or services for
which payment may be made under a federal healthcare program such as the Medicare and Medicaid
programs;

• U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly
presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party
payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim
including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a
false or fraudulent claim for purposes of the false claims statutes;

•

the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices
and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;

• HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which
governs the conduct of certain electronic healthcare transactions and protects the security and privacy of
protected health information; and

•

state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false
claims laws, which may apply to items or services reimbursed by any third-party payor, including
commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance
environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different
compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or
more of these requirements. In addition, any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the
operation of our business. If our operations are found to be in violation of any of the laws described above or any
other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal
penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring
of our operations, any of which could adversely affect our ability to operate our business, results of operations and
financial condition.

We may incur losses in future periods due to write-downs in the value of financial instruments.

We have positions in a variety of financial instruments including asset backed securities and other similar
instruments. Financial markets are quite volatile and the markets for these securities can be illiquid. The value of
these securities will continue to be impacted by external market factors including default rates, changes in the value
of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which
observable market transactions occur and the financial strength of various entities, such as financial guarantors who
provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell
these instruments without significant losses due to current debtor financial conditions or other market
considerations.

Regulations related to “conflict minerals” could adversely impact our business.

As part of the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC adopted disclosure
requirements regarding the use of certain minerals, known as conflict minerals, which are mined from the
Democratic Republic of Congo (DRC) and adjoining countries, as well as procedures regarding a manufacturer's
efforts to identify the sourcing of such minerals and metals produced from those minerals. The European Union is
considering additional reporting obligations. We have incurred, and will continue to incur, additional costs in order
to comply with the SEC’s disclosure requirements. In addition, we might incur further costs due to possible
changes to our products, processes, or sources of supply as a consequence of our due diligence activities. As our
supply chain is complex, we may not be able to sufficiently verify the origins of the specified minerals used in our
products through our due diligence procedures, which may harm our reputation. In addition, we may encounter
challenges to satisfy those customers who require that all of the components of our products be certified as “DRC
conflict free”, which could place us at a competitive disadvantage if we do not do so. We filed our report for the
calendar year 2013 with the SEC on May 30, 2014.

Risks related to our common stock

A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.

We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions,
holders of Class A and Class B Common Stock vote as a single class. When voting as a single class, each share of
Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote.
In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are
entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining
directors.

As of February 17, 2015, the Schwartz family collectively held approximately 15% of our Class A Common Stock
and 94% of our Class B Common Stock. As a result, the Schwartz family is able to elect a majority of the directors,
effect fundamental changes in our direction and control matters affecting us, including the determination of
business opportunities that may be suitable for our company. The Schwartz family may exercise its control over us
according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of
ownership and voting power may have the effect of delaying or preventing a change in control of our company.

ITEM 1B. UNRESOLVED STAFF COMMENTS
None.

ITEM 2. PROPERTIES

We own our corporate headquarters located in Hercules, California. The principal manufacturing and research
locations for each segment are as follows:

Segment

Location

Life Science

Clinical
Diagnostics

Richmond, California
Hercules, California
Pleasanton, California
Singapore
Shanghai, China
Oxford, England

Hercules, California
Benicia, California
Irvine, California
Greater Seattle area, Washington
Lille, France
Greater Paris area, France
Nazareth-Eke, Belgium
Cressier, Switzerland
Dreieich, Germany

Owned/Leased

Owned/Leased
Owned/Leased
Leased
Leased
Leased
Leased

Owned/Leased
Leased
Leased
Leased
Owned
Leased
Leased
Owned/Leased
Owned/Leased

Most manufacturing and research facilities also house administration, sales and distribution activities. In addition,
we lease office and warehouse facilities in a variety of locations around the world. The facilities are used
principally for sales, service, distribution and administration for both segments.

ITEM 3. LEGAL PROCEEDINGS

As previously disclosed, in May 2010 we voluntarily disclosed to the U.S. Department of Justice (DOJ) and the
Securities and Exchange Commission (SEC) certain likely or potential violations of the U.S. Foreign Corrupt
Practices Act (FCPA). The Audit Committee of our Board of Directors (Audit Committee) assumed direct
responsibility for reviewing these matters and hired experienced independent counsel to conduct an investigation
and provide legal advice. The SEC and DOJ each commenced its own investigation. During and following the
completion of the Audit Committee’s investigation, we provided information to the DOJ and SEC and cooperated
with their investigations.

Effective November 3, 2014, we entered into a non-prosecution agreement (NPA) with the DOJ and consented to
the entry of an Order by the SEC (SEC Order), which actions resolve both the DOJ and the SEC investigations.
The NPA concerns violations of the FCPA’s books and records and internal control provisions related to Russia
during 2005-2010. Pursuant to the NPA, we paid a penalty of $14.4 million and agreed to certain compliance,
reporting and cooperation obligations, and the DOJ agreed that it will not criminally prosecute us for any crimes
related to conduct disclosed to the DOJ, provided that we perform our obligations under the NPA for two years.

The SEC Order concerns violations of the FCPA’s books and records, internal controls, and anti-bribery provisions
related to Russia, and violations of the FCPA’s books and records and internal controls provisions related to
Vietnam and certain of our Thailand operations during 2005-2010. Pursuant to the SEC Order, we paid a total of
$40.7 million that included $35.1 million in disgorgement and $5.6 million in interest, and agreed to make certain
reports to the SEC on our anti-corruption compliance and remediation efforts over the next two years, and to cease
and desist any violations of the FCPA.

In the NPA and the SEC Order, the DOJ and the SEC, respectively, took into account our initial voluntary self-
disclosure of the potential FCPA violations, our own extensive investigation and cooperation with their
investigations and our extensive and significant remediation efforts to date. Neither the NPA nor the SEC Order
requires the appointment of an independent external monitor to oversee our activities or our compliance with
applicable laws.

On April 13, 2011, a shareholder derivative lawsuit was filed against each of our directors in the Superior Court for
Contra Costa County, California. The case, which also named the Company as a nominal defendant, was captioned
City of Riviera Beach General Employees’ Retirement System v. David Schwartz, et al. In the complaint, the
plaintiff alleged that our directors breached their fiduciary duties by failing to ensure that we had sufficient internal
controls and systems for compliance with the FCPA. Purportedly seeking relief on our behalf, the plaintiff sought
an award of unspecified compensatory and punitive damages, costs and expenses (including attorneys’ fees), and a
declaration that our directors breached their fiduciary duties. The parties agreed to a stipulated dismissal of this
case, without prejudice, and to a tolling of the statute of limitations pending the resolution of the DOJ and SEC
investigations, which occurred in November 2014, as disclosed above.

On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a new shareholder
derivative lawsuit in the Superior Court of Contra Costa County against three of our current directors and one
former director. The Company is also named as a nominal defendant. In the complaint, the plaintiff alleges that the
Company’s directors breached their fiduciary duty of loyalty by failing to ensure that the Company had sufficient
internal controls and systems for compliance with the FCPA; that the Company failed to provide adequate training
on the FCPA; and that based on these actions, the directors have been unjustly enriched. Purportedly seeking relief
on the Company’s behalf, the plaintiff seeks an award of restitution and unspecified damages, costs and expenses
(including attorneys’ fees). We and the individual defendants intend to file a demurrer requesting dismissal of the
complaint.

On January 30, 2015, we received a demand pursuant to Section 220 of the Delaware General Corporation Law
from the law firm of Scott + Scott LLP on behalf of International Brotherhood of Electrical Workers Local 38
Pension Fund to inspect certain books and records of the Company. The alleged purpose of the demand is to
investigate the Company’s violation of the FCPA and lack of internal controls.

In addition, we are party to various other claims, legal actions and complaints arising in the ordinary course of
business. We do not believe, at this time, that any ultimate liability resulting from any of these other matters will
have a material adverse effect on our results of operations, financial position or liquidity. However, we cannot give
any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our
operating results for any particular period, depending on the level of income for the period.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II.

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER

MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Information Concerning Common Stock

Bio-Rad’s Class A and Class B Common Stock are listed on the New York Stock Exchange with the symbols BIO
and BIO.B, respectively. The following sets forth, for the periods indicated, the high and low intraday sales prices
for our Class A and Class B Common Stock.

2014
Fourth Quarter
Third Quarter
Second Quarter
First Quarter
2013
Fourth Quarter
Third Quarter
Second Quarter
First Quarter

Class A

Class B

High

Low

High

Low

122.93
122.73
131.42
134.13

125.00
126.98
127.17
126.50

102.71
113.37
117.98
120.43

115.25
111.49
110.02
106.10

120.50
122.40
128.70
135.60

124.41
122.95
125.50
125.00

108.80
115.60
118.40
121.10

115.59
114.00
110.75
106.75

On February 17, 2015, we had 321 holders of record of Class A Common Stock and 133 holders of record of Class
B Common Stock. Bio-Rad has never paid a cash dividend and has no present plans to pay cash dividends.

See Item 12 of Part III of this report for the security ownership of certain beneficial owners and management and
for securities authorized for issuance under equity compensation plans.

Stock Performance Graph

The following graph compares the cumulative stockholder returns over the past five years for our Class A Common
Stock, the S&P 400 MidCap Index and a selected peer group, assuming $100 invested on December 31, 2009, and
reinvestment of dividends if paid:

(1) The Peer Group consists of the following public companies: Danaher, Becton Dickinson, Thermo Fisher
Scientific, Meridian Bioscience and PerkinElmer. Life Technologies, which was included in the peer group last
year, was dropped from the peer group as it was acquired during 2014 by Thermo Fisher Scientific. Elimination of
the Life Technologies historical data did not significantly change the performance of the peer group. Companies in
our peer group reflect our participation in two different markets: life science research products and clinical
diagnostics. No single public or private company has a comparable mix of products which serve the same markets.
In many cases, only one division of a peer-group company competes in the same market as we do. Collectively,
however, our peer group reflects products and markets similar to those of Bio-Rad.

This stock performance graph shall not be deemed incorporated by reference by any general statement
incorporating by reference into any filing under the Securities Act or the Exchange Act, and shall not otherwise be
deemed filed under these Acts.

ITEM 6. SELECTED FINANCIAL DATA

BIO-RAD LABORATORIES, INC.
Selected Financial Data
(in thousands, except per share data)

Net sales

Cost of goods sold

Gross profit

Selling, general and administrative expense
Research and development expense

Interest expense
Foreign exchange losses, net

Other (income) expense, net

Income before income taxes
Provision for income taxes
Net income attributable to noncontrolling
interests

Net income attributable to Bio-Rad

Basic earnings per share
Diluted earnings per share
Cash dividends paid per common share
Total assets
Long-term debt, net of current maturities

$
$
$
$
$

2014

2013

Year Ended December 31,
2012

2011

2010

2,175,044
996,527
1,178,517
808,200
220,333

22,131
9,305
(13,009)

131,557
(42,712)

2,132,694
954,216
1,178,478
798,070
210,952

61,271
8,566
(12,766)

112,385
(34,574)

2,069,235
914,077
1,155,158
681,778
209,204

51,112
5,040
(21,883)

229,907
(64,361)

2,073,529
894,700
1,178,829
695,984
177,604

53,135
13,842
(7,583)

245,847
(67,034)

—
88,845

(21)
77,790

(69)
165,477

200
179,013

3.08
3.05

$
$
— $
$
$

3,341,278
435,710

2.72
2.69

$
$
— $
$
$

3,388,790
435,615

5.85
5.78

$
$
— $
$
$

3,443,503
732,414

6.39
6.29

$
$
— $
$
$

3,099,743
731,698

1,927,118
835,310
1,091,808
634,413
166,486

63,717
3,884
(3,875)

227,183
(39,533)

(1,445)
186,205

6.73
6.61
—
3,064,914
731,100

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

This discussion should be read in conjunction with the information contained in our consolidated financial
statements and the accompanying notes which are an integral part of the statements.

Overview. We are a multinational manufacturer and worldwide distributor of our own life science research and
clinical diagnostics products. Our business is organized into two primary segments, Life Science and Clinical
Diagnostics, with the mission to provide scientists with specialized products needed for biological research and
clinical diagnostics.

We sell more than 8,000 products and services to a diverse client base comprised of scientific research, healthcare,
education and government customers worldwide. We do not disclose quantitative information about our different
products and services as it is impractical to do so based primarily on the numerous products and services that we
sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex
chemical and biological materials and to identify, analyze and purify components. Because our customers require
standardization for their experiments and test results, much of our revenues are recurring.

We are impacted by the support of many governments for both research and healthcare. The current global
economic outlook is still uncertain as the need to control government social spending by many governments limits
opportunities for growth. Approximately 32% of our 2014 consolidated net sales are derived from the United States
and approximately 68% are derived from international locations, with Europe being our largest region overall. The
international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese
Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar
weakens and suffer when the dollar strengthens. When the U.S. dollar strengthens, we benefit from lower cost of
sales from our own international manufacturing sites as well as non-U.S. suppliers and from lower international
operating expenses.

As previously disclosed, in May 2010 we voluntarily disclosed to the U.S. Department of Justice (DOJ) and the
Securities and Exchange Commission (SEC) certain likely or potential violations of the U.S. Foreign Corrupt
Practices Act (FCPA). Effective November 3, 2014, we entered into a non-prosecution agreement (NPA) with the
DOJ and consented to the entry of an Order by the SEC (SEC Order), which actions resolve both the DOJ and SEC
investigations. As a result of the settlements with the DOJ and the SEC, during the fourth quarter of 2014 we paid a
total of $55.1 million that included a penalty of $14.4 million, $35.1 million in disgorgement, and $5.6 million in
interest.

In April 2014, we acquired 100% of the issued and outstanding stock of GnuBIO, Inc. (GnuBIO). This acquisition
was accounted for as a business combination and is included in our Clinical Diagnostics segment's results of
operations from the acquisition date. The excess of purchase consideration over the fair value of net tangible and
identifiable intangible assets acquired was recorded as goodwill. The fair values assigned to tangible and
identifiable intangible assets acquired and liabilities assumed are based on management’s estimates and
assumptions. During the fourth quarter of 2014, we finalized the determination of fair values of certain acquired tax
attributes and adjusted the preliminary carrying values of goodwill and certain other assets and liabilities in order to
reflect final information received and the finalization of certain tax returns, resulting in an overall reduction to
goodwill of $1.7 million. These measurement period adjustments had no impact on our results of operations for the
year ending December 31, 2014.

The final fair values of the net assets acquired from GnuBIO as of the acquisition date were determined to be
$46.4 million of indefinite-lived intangible assets (specifically in-process research and development or "IPR&D"),
$13.5 million of goodwill and $9.5 million of net tangible liabilities. The fair value of the consideration as of the

acquisition date was $50.4 million, which included $39.7 million paid in cash at the closing date and $10.7 million
in contingent consideration potentially payable to GnuBIO's shareholders. The contingent consideration was based
on a probability-weighted income approach that could reach $70.0 million upon the achievement of all
development/regulatory and sales milestones. The contingent consideration for the development/regulatory
milestones was valued at $10.7 million, based on assumptions regarding the probability of achieving the milestones,
with such amounts discounted to present value. During the fourth quarter of 2014, the contingent consideration
related to the development/regulatory milestones was revalued to a fair value of $10.0 million as of December 31,
2014. The contingent consideration for the sales milestones at the acquisition date was determined to be negligible,
using the risk-neutral probability of being in the money based on a Black-Scholes framework. We believe that
GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and will leverage
our leadership role in the area of droplet digital PCR.

In January 2013, we acquired 100% of the outstanding shares of AbD Serotec, a division of MorphoSys AG, for
total consideration of $62.2 million (net of cash received of $7.3 million). This acquisition was accounted for as a
business combination and is included in our Life Science segment's results of operations from the acquisition date.
The final fair values of the net assets acquired consist of definite-lived intangible assets of $44.0 million, goodwill
of $14.9 million and net tangible assets of $3.3 million. We believe that with AbD Serotec's comprehensive catalog
of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research
platforms for western blotting, multiplex protein expression, ELISA and cell sorting.

In September 2013, we redeemed all of our $300.0 million 8.0% Senior Subordinated Notes for $312.0 million,
including a call premium of $12.0 million, and expensed the remaining original issuance bond discount of $2.5
million and unamortized bond issuance costs of $1.1 million, all of which are included in Interest expense in our
Condensed Consolidated Statements of Income.

During the third quarter of 2014, we identified errors in the Consolidated Balance Sheet at December 31, 2013, the
Consolidated Statements of Cash Flows for the years ended December 31, 2013 and 2012 (and for all interim
periods therein), and in the Unaudited Condensed Consolidated Balance Sheets and Statements of Cash Flows as of
and for the three months ended March 31, 2014 and the three and six months ended June 30, 2014, all related to the
recorded amounts of Inventories and Property, plant and equipment, net. During these periods, we inappropriately
reduced Inventories by all of the intercompany profit on intercompany transactions related to certain equipment,
however, a portion of that profit should have reduced capital additions and been reflected in Property, plant and
equipment, net. The equipment is a Bio-Rad product provided to customers under reagent rental agreements,
whereby Bio-Rad retains ownership of the equipment and charges the customer for test kits purchased for use with
this equipment. Depreciation was calculated correctly, and there is no impact to Net income for any period
presented.

The effect of correcting these errors was to increase Total inventories and decrease Property, plant and equipment,
net at December 31, 2013 by $15.0 million. As a result of this adjustment, $5.3 million of prepaid income taxes
that were included in Prepaid expenses on the Consolidated Balance Sheet as of December 31, 2013 were
reclassified from short-term to long-term Other assets. The overall effect of the adjustments to Total inventories
and Prepaid expenses increased Total current assets by $9.6 million. These adjustments did not change Total assets.

The associated reclassification entries within the Statements of Cash Flows were to increase Cash paid to suppliers
and employees, and decrease Capital expenditures by $6.3 million and $9.5 million for the years ended December
31, 2013 and 2012, respectively. These reclassifications resulted in a decrease in Net cash provided by operating
activities and a decrease in Net cash used in investing activities by $6.3 million and $9.5 million for the years ended
December 31, 2013 and 2012, respectively. There was no change to the net increase or decrease in Cash and cash
equivalents for any period presented.

significant to the periods impacted, their correction would not be material to any individual prior period nor did
they have an effect on financial results. Accordingly, we are correcting these errors in every affected period in our
Consolidated Financial Statements.

During the third quarter of 2012, we recognized a contingent consideration liability of $44.6 million upon our
acquisition of a new cell sorting system from Propel Labs, Inc. The fair value of the contingent consideration was
based on a probability-weighted income approach related to the achievement of certain development and sales
milestones. The development milestone was achieved and paid in 2013. In the third quarter of 2014, the first sales
milestone was reached with cell sorting system purchase orders resulting in a payment of $2.4 million in the fourth
quarter of 2014. Effective as of December 31, 2014, we have amended certain key terms impacting the future
payment of contingent consideration on the acquisition of the new cell sorting system from Propel Labs, Inc. These
include a clarification of the performance period to include an additional four months, and the seller agreeing to
support an expansion of our offerings to address the request from customers for customization. The amended sales
milestones range from 39% of annual invoices for the 2015 and 2016 annual calendar year performance periods to
40% for the extended September 1, 2013 to December 31, 2014 performance period. The contingent consideration
was revalued by a net reduction of $0.7 million in 2014 to Selling, general and administrative expense to its
estimated fair value of $17.7 million as of December 31, 2014.

Critical Accounting Policies and Estimates

The accompanying discussion and analysis of our financial condition and results of operations are based upon our
consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting
principles (GAAP). The preparation of financial statements in conformity with GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets, liabilities and contingencies as of the
date of the financial statements and reported amounts of revenues and expenses during the reporting periods. We
evaluate our estimates on an on-going basis. We base our estimates on historical experience and on other
assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
However, future events may cause us to change our assumptions and estimates, which may require adjustment.
Actual results could differ from these estimates. We have determined that for the periods reported in this Annual
Report on Form 10-K the following accounting policies and estimates are critical in understanding our financial
condition and results of operations.

Accounting for Income Taxes. Management is required to make estimates related to our income tax provision in
each of the jurisdictions in which we operate. This process involves estimating our current tax exposures, as well as
making judgments regarding the recoverability of deferred tax assets in each jurisdiction. Deferred tax assets and
liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets
and liabilities for financial reporting purposes and the amounts used for income tax purposes. Management
assesses the likelihood that the deferred tax assets will be recovered from future taxable income and to the extent
management believes that recovery is not likely, a valuation allowance must be established. To the extent
management establishes a valuation allowance or increases this allowance in a period, an increase to expense within
the Provision for income taxes in the Consolidated Statements of Income may result.

We have recorded a valuation allowance of $58.6 million and $64.0 million as of December 31, 2014 and 2013,
respectively, due to uncertainties related to our ability to utilize some of the deferred tax assets, primarily consisting
of certain foreign net operating losses carried forward. The valuation allowance is based on management’s current
estimates of taxable income for the jurisdictions in which we operate and the period over which the deferred tax
assets will be recoverable. In the event that actual results differ from these estimates, or these estimates are
adjusted in future periods, an additional valuation allowance may need to be established, which would increase the
tax provision, lowering income and impacting our financial position. Should realization of these deferred tax assets
for which a valuation allowance has been provided occur, the provision for income taxes may decrease, raising
income and positively impacting Bio-Rad’s financial position.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position
will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax
benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit
that has a greater than 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits
is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax
law, new regulations or interpretations by the taxing authorities, new information obtained during a tax
examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate,
related to unrecognized tax benefits in income tax expense. Our overall effective tax rate is subject to fluctuations
because of changes in the geographic mix of earnings, changes to statutory tax rates and tax laws, and because of
the impact of various tax audits and assessments, as well as generation of tax credits.

Valuation of Goodwill and Long-lived Assets. Goodwill represents the excess of the cost over the fair value of net
tangible and identifiable intangible assets of acquired businesses. Goodwill amounts are assigned to reporting units
at the time of acquisition and are adjusted for any subsequent significant transfers of business between reporting
units. We assess the impairment of goodwill annually in the fourth quarter or whenever events or changes in
circumstances indicate that the carrying value may not be recoverable. We perform the impairment tests of
goodwill at our reporting unit level, which is one level below our operating segments. The goodwill impairment
test consists of a two-step process. The first step of the goodwill impairment test, used to identify potential
impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. If the fair value of
the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the
second step of the impairment test is not required. The second step, if required, compares the implied fair value of
the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated
to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit
had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire
the reporting unit. If the carrying amount of the reporting unit's goodwill exceeds its implied fair value, an
impairment charge is recognized in an amount equal to that excess.

We use a projected discounted cash flow model to determine the fair value of a reporting unit. This discounted cash
flow method for determining goodwill may be different from the fair value that would result from an actual
transaction between a willing buyer and a willing seller. Projections such as discounted cash flow models are
inherently uncertain and accordingly, actual future cash flows may differ materially from projected cash flows.
Management judgment is required in developing the assumptions for the discounted cash flow model. These
assumptions include revenue growth rates, profit margins, future capital expenditures, working capital needs,
expected foreign currency rates, discount rates and terminal values. We estimate future cash flows using current
and longer-term high level financial forecasts. These forecasts take into account the current economic environment.
The discount rates used are compiled using independent sources, current trends in similar businesses and other
observable market data. Changes to these rates might result in material changes in the valuation and determination
of the recoverability of goodwill. For example, an increase in the discount rate used to discount cash flows will
decrease the computed fair value.

We have not identified any events that lead us to believe that goodwill is impaired. However, impairment tests are
highly sensitive to changes in assumptions and minor changes to assumptions that could result in impairment losses.
Our forecasts utilized in our 2014 impairment test assumed, among other things, sales growth from executing our
sales and marketing programs, new product introductions, successful product development and timely registration
of our products when required, while controlling costs. In addition, external factors, such as currency, inflation
rates and cost of capital, could affect the determination of fair value of our business units. Our impairment tests
resulted in excessive fair value over book value ranging from 17% to more than 200% for our various business
units. Two of our business units had an excess of 17% and 28%, respectively. If the initiatives mentioned above do
not achieve the desired results, or external factors change detrimentally, future impairment losses may occur.

To validate the reasonableness of the reporting unit fair values, we reconcile the aggregate fair values of the
reporting units to the enterprise market capitalization. In performing the reconciliation we may, depending on the
volatility of the market value of our stock price, use either the stock price on the valuation date or the average stock
price over a range of dates around the valuation date.

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with
other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash
flows of other assets and liabilities. We assess the impairment of long-lived assets (including identifiable
intangibles) whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
Factors that we consider important that could trigger an impairment review include:

•

significant reporting unit under-performance relative to expected, historical or projected future operating
results;
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our
overall business;
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of
before the end of its previously estimated useful life; and
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the
existence of one or more of the above indicators of impairment, we test for any impairment based on a projected
undiscounted cash flow method. Projected future operating results and cash flows of the asset or asset group are
used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets. We
estimate the future cash flows of the long-lived assets using current and long-term financial forecasts. The carrying
amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to
result from the use and eventual disposition of the asset. If this is the case, an impairment loss would be
recognized. The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.
There were no impairment losses recorded in 2013 and 2012. In 2014, we impaired licenses of a discontinued
product line in the amount of $6.4 million. This impairment charge included $5.8 million in Cost of goods sold
and $0.6 million in Research and development expense in the accompanying Consolidated Statements of Income.

Valuation of Inventories. We value inventory at the lower of the actual cost to purchase and/or manufacture the
inventory, or the current estimated net realizable value of the inventory. We review inventory quantities on hand
and reduce the cost basis of excess and obsolete inventory based primarily on an estimated forecast of product
demand, production requirements and the quality, efficacy and potency of raw materials. This review is done on a
quarterly basis or, if warranted by the circumstances, more frequently. In addition, our industry is characterized by
technological change, frequent new product development and product obsolescence that could result in an increase
in the amount of obsolete inventory quantities on hand. Our estimates of future product demand may prove to be
inaccurate, and if too high, we may have overstated the carrying value of our inventory. In the future, if inventory is
determined to be overvalued, we would be required to write down the value of inventory to market and recognize
such costs in our cost of goods sold at the time of such determination. Therefore, although we make efforts to
ensure the accuracy of our forecasts of future product demand and perform procedures to safeguard overall
inventory quality, any significant unanticipated changes in demand, technological developments, regulations,
storage conditions, or other economic or environmental factors affecting biological materials, could have a
significant impact on the value of our inventory and reported results of operations.

Valuation of Investments. We regularly review our investments for factors that may indicate that a decline in the
fair value of an investment below its carrying value is other-than-temporary. Some factors considered in evaluating
whether or not a decline in fair value is other-than-temporary include our ability and intent to retain the investment
for a period of time sufficient to allow for a recovery in value, the duration and extent to which the fair value has
been less than cost and the financial condition and prospects of the issuer. Such reviews are inherently uncertain in
that the value of the investment may not fully recover or may decline further in future periods resulting in realized
losses.

Warranty Reserves. We warrant certain equipment against defects in design, materials and workmanship,
generally for a period of one year. Upon delivery and on acceptance of that equipment, we establish, as part of cost
of goods sold, a provision for the expected costs of such warranty repairs based on historical experience, specific
warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our
warranty reserve and it is adjusted if necessary. The warranty reserve is based on actual experience and expected
future costs to be incurred. Should realized costs be higher than expected costs, cost of goods sold would be lower
in the period of estimation and higher when realized.

Allowance for Doubtful Accounts. We maintain an allowance for doubtful accounts for estimated losses resulting
from the collectability of our customer accounts. The amount of the allowance is determined by analyzing known
uncollectible accounts, the age of our receivables, economic conditions in the customers’ country or industry,
historical losses and our customers’ general credit-worthiness. Amounts later determined and specifically identified
to be uncollectible are charged or written off against this allowance. Uncertainty in the current economic
environment, if prolonged, could result in greater amounts becoming uncollectible in the future. Should the
estimates of losses be higher than the actual uncollectible accounts, we would report lower profitability when the
estimates are made and higher profitability when the receivable is collected.

Litigation Accruals. We record as liabilities in our Consolidated Balance Sheets estimated amounts for claims that
are probable and can be reasonably estimated. The likelihood of a material change in these estimated liabilities is
dependent on the possible outcome of settlement negotiations, regulatory or judicial review and the development of
facts and circumstances in extended litigation which could change claims or assessments when both the amount and
range of loss on some outstanding litigation is uncertain. We disclose in the footnotes of the financial statements
when we are unable to make a reasonable estimate of a material liability that could result from unfavorable
outcomes in litigation. As events occur, we will assess the potential liability related to our pending litigation and
revise our estimates. Such revisions could materially impact our results of operations.

Results of Operations - Sales, Gross Margins and Expenses

The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales:

Net sales
Cost of goods sold
Gross profit
Selling, general and administrative expense
Research and development expense
Net income attributable to Bio-Rad

Net sales

2014

Year Ended December 31,
2013

2012

100.0%
45.8
54.2
37.2
10.1
4.1

100.0%
44.7
55.3
37.4
9.9
3.6

100.0%
44.2
55.8
32.9
10.1
8.0

Net sales (sales) in 2014 were $2.18 billion, an increase of 2.0% compared to $2.13 billion in 2013. Excluding the
impact of foreign currency, 2014 sales increased by approximately 3.3% compared to 2013. Currency neutral sales
growth was reflected in most regions, primarily in the United States, the emerging markets of Eastern Europe and
China, while currency neutral sales in Japan decreased.

The Life Science segment sales in 2014 were $728.3 million, an increase of 2.6% compared to 2013. On a currency
neutral basis, sales increased 4.0% compared to 2013. The currency neutral sales increase was reflected across
most product lines, except for protein separations products. Currency neutral sales growth was primarily in North
America, Europe, and China, partially offset by decreased sales in the rest of Asia.

The Clinical Diagnostics segment sales in 2014 were $1.43 billion, an increase of 1.7% compared to 2013. On a
currency neutral basis, sales increased 2.9% compared to 2013. Clinical Diagnostics had growth across most
product lines on a currency neutral basis, most notably from quality control products and blood typing. Sales
growth was partially offset by lower sales for infectious disease in the serology product line primarily due to
laboratory consolidation and pricing pressure in Europe and North America. Currency neutral sales growth was
primarily in Eastern Europe and China, partially offset by decreased sales in Western Europe.

Net sales (sales) in 2013 were $2.13 billion compared to $2.07 billion in 2012. Excluding the impact of foreign
currency, 2013 sales increased by approximately 3.9% compared to 2012. Currency neutral sales growth was
reflected in most regions, primarily in the Americas, the emerging markets of Eastern Europe and the Pacific Rim,
while currency neutral sales in Western Europe decreased.

The Life Science segment sales in 2013 were $710.0 million, an increase of 3.1% compared to 2012. On a currency
neutral basis, sales increased 4.5% compared to 2012. The sales increase was primarily driven by sales from the
newly acquired AbD Serotec, our Droplet Digital™ PCR and cell biology product lines. Currency neutral sales
increased in Europe and the Americas, while Asia declined. A government austerity program had slowed Japanese
market growth.

The Clinical Diagnostics segment sales in 2013 were $1.41 billion, an increase of 3.1% compared to 2012. On a
currency neutral basis, sales increased 3.6% compared to 2012. Clinical Diagnostics had growth across most
product lines on a currency neutral basis, most notably from quality controls, diabetes and BioPlex® 2200 system.
Currency neutral sales growth was primarily in Eastern Europe, China, Asia Pacific and the Americas, while
currency neutral sales in Western Europe declined.

Gross margin

Consolidated gross margins were 54.2% in 2014 compared to 55.3% in 2013. Life Science segment gross margins
in 2014 decreased from 2013 by approximately 0.1 percentage points, essentially flat compared to 2013. Lower
margins were reflected in protein separation products and approximately $1.7 million of costs associated with the
closing of a small manufacturing plant, which were almost entirely offset by higher margins in process
chromatography, Droplet Digital™ PCR and food testing products. Clinical Diagnostics segment gross margins in
2014 decreased from 2013 by approximately 1.5 percentage points. The decrease primarily reflected approximately
$8.3 million associated with the discontinuance of a product line in 2014 that was coupled with an increase in
inventory reserves and the write-down of licenses for specific technology. The decrease was also due to continued
pricing pressure, approximately $1.6 million associated with closing and consolidating two small manufacturing
plants in 2014, and increased scrap for obsolete products.

Beginning in 2013, the Patient Protection and Affordable Health Care and the Health Care and Education
Reconciliation Acts of 2010, among other initiatives, provided for a 2.3% annual excise tax on the sales of certain
medical devices in the U.S. Bio-Rad was required to pay this excise tax on most of our U.S. Clinical Diagnostic
sales, which we accounted for as a period cost in Cost of goods sold.

Consolidated gross margins were 55.3% in 2013 compared to 55.8% in 2012. Life Science segment gross margins
in 2013 increased from 2012 by approximately 0.5 percentage points primarily due to an incremental royalty
accrual related to a dispute with a third party, as well as a $3.8 million soil remediation expense associated with a
manufacturing plant, both of which occurred in 2012. The increase was partially offset by an increase in costs
related to inventory sold with a higher cost due to purchase accounting, and an increase in purchased intangibles
amortization expense of $6.1 million primarily related to the AbD Serotec and cell sorting system acquisitions.
Clinical Diagnostics segment gross margins in 2013 decreased from 2012 by approximately 1.2 percentage points
primarily due to some large low margin government tenders, a less favorable product mix, and an increase in
obsolescence charges. Gross margins also decreased by approximately 0.36% due to the excise tax on the sales of
certain medical devices in the U.S. that went into effect in 2013. Clinical Diagnostics segment lower gross margins

were partially offset by a foreign supplemental tax associated with social benefits of $4.1 million that occurred in
2012, and a $0.6 million French Competitiveness Tax Credit that was recorded in 2013.

Selling, general and administrative expense

Consolidated selling, general and administrative expenses (SG&A) represented 37.2% of sales in 2014 compared to
37.4% of sales in 2013. Decreases in SG&A expense relative to sales were primarily driven by:

• we accrued a lower expense of $19.5 million in 2014 compared to an accrual of $30.0 million in 2013 in
connection with reaching our final settlement with the SEC and DOJ investigations relating to the FCPA,
lower external marketing and advertising expense, and professional fees, and
a decrease in bad debt expense of $4.0 million, primarily in Russia, due to a distributor bad debt in 2013,
and in Spain due to payments received of approximately $11 million from public agencies, in addition to
improved collections in the U.S. after implementing the first phase of a new ERP system.

•
•

Partially offsetting these decreased costs were:

•

•
•

an increase of employee-related expenses, our largest cost, primarily due to an increase for employee
compensation that comprised of incentive plans, including related fringe benefits, and commissions and
temporary help associated with our ERP implementation,
$1.4 million in 2014 for the net decrease in estimated fair value of contingent considerations for the cell
sorting system and GnuBIO, compared to $5.8 million in 2013 for the net decrease in estimated fair value
of contingent consideration for the cell sorting system and a write-off of the remaining QuantaLife
contingent consideration liability, resulting in an overall increase in contingent consideration of
$4.4 million,
an increase in third party commissions and facilities, and
an increase in software costs primarily associated with the ERP implementation.

Consolidated selling, general and administrative expenses (SG&A) represented 37.4% of sales in 2013 compared to
32.9% of sales in 2012. Increases in SG&A expense relative to sales were primarily driven by:

•

an increase of $43.6 million of employee-related expenses, our largest cost, associated with an increase in
headcount that included acquisitions,
an accrual of $30.0 million in connection with our initial efforts to resolve the SEC and DOJ investigations
relating to the FCPA that was recorded in the latter half of 2013,
an increase in professional services of $21.7 million primarily related to the first phase of a global single
instance ERP system being placed in service, and legal and accounting services,
the favorable impact of a 2012 revaluation to the fair value of the QuantaLife contingent consideration of
$16.1 million,
an increase of $9.6 million in software amortization primarily due to the first phase of the ERP platform
being placed in service,
an increase of $6.5 million in facilities primarily due to an expansion at our southern California facility and
our acquisition of AbD Serotec,
an increase of $5.7 million as 2012 benefited from lower bad debt expense, primarily in Spain due to a
large sum of payments by public agencies, causing us to revise our estimate for the allowance for doubtful
accounts, partially offset by
a decrease in the valuation of the cell sorting system contingent consideration of $3.8 million in 2013.

Research and development expense

Research and development expense increased to $220.3 million or 10.1% of sales in 2014 compared to
$211.0 million or 9.9% of sales in 2013. Life Science segment research and development expense decreased
slightly in 2014 from 2013 primarily due to projects nearing completion. Clinical Diagnostics segment research
and development expense increased in 2014 from 2013 primarily due to continued investments in diagnostic
applications using the recently acquired droplet digital PCR technology, and new instrument platforms and assays.

The increase also reflected approximately $3.1 million associated with the discontinuance of a product line in 2014
that included contractual costs, and the write-down of equipment and licenses.

Research and development expense increased to $211.0 million or 9.9% of sales in 2013 compared to
$209.2 million or 10.1% of sales in 2012. Life Science segment research and development expense decreased in
2013 from 2012 primarily due to projects nearing completion. Clinical Diagnostics segment research and
development expense increased in 2013 from 2012 primarily due to lower refundable French R&D tax credits, and
a broadening of on-going development across a wider range of products.

Results of Operations – Non-operating

Interest expense

Interest expense in 2014 decreased 63.9% to $22.1 million compared to 2013 primarily due to the absence of
interest expense of $18.7 million and $15.6 million associated with a call premium, and expensing the remaining
original bond discount and unamortized debt issuance costs associated with the $300.0 million principal amount of
Senior Subordinated Notes (8.0% Notes), which were redeemed on September 30, 2013. In addition, interest
expense in connection with reaching our final settlement with the SEC and DOJ investigations relating to the FCPA
was $0.6 million for 2014 compared to $5.0 million for 2013.

Interest expense in 2013 increased 19.9% to $61.3 million compared to 2012 primarily due to the early redemption
of our 8.0% Notes on September 30, 2013, resulting in a $15.6 million expense. The redemption included a call
premium of $12.0 million, the expensing of $2.5 million of the remaining original issuance bond discount and the
expensing of unamortized debt issuance costs of $1.1 million. In addition, Interest expense included an expense of
$5.0 million of interest expense associated with our initial efforts to resolve the DOJ and SEC investigations
relating to the FCPA that was recorded in the latter half of 2013. The increase was partially offset by estimated
interest expense of $1.2 million included in the first quarter of 2012 that was associated with a foreign supplemental
tax related to social benefits, and interest on back royalties in 2012.

Foreign currency exchange gains and losses

Foreign currency exchange gains and losses consist of foreign currency transaction gains and losses on
intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts
used to manage our foreign currency exchange risk. Net foreign currency exchange losses for 2014, 2013 and 2012
were $9.3 million, $8.6 million and $5.0 million, respectively. The 2014, 2013 and 2012 net foreign currency
exchange losses were attributable to market volatility, increasing costs to hedge and the result of the estimating
process inherent in the timing of shipments and payments of intercompany debt. All years are affected by the
economic hedging program we employ to hedge our intercompany receivables and payables.

Other income and expense, net

Other income and expense, net includes investment and dividend income, generally interest income on our cash and
cash equivalents, short-term investments and long term marketable securities. Other (income) expense, net in 2014
increased to $13.0 million income compared to $12.8 million income in 2013. The increase was primarily due to
higher dividends than in 2013, and realized gains in 2014 compared to realized losses in 2013, partially offset by
lower interest on investment income than in 2013. Sales of investments in 2013 were used to provide cash to
redeem all of the $300.0 million 8.0% Senior Subordinated Notes.

Other (income) expense, net in 2013 decreased to $12.8 million income compared to $21.9 million income in 2012.
The decrease was primarily due to higher realized gains associated with the sale of equity investments in 2012
compared to realized losses in 2013, and a 2012 gain of $4.3 million on the sale of a building in our Clinical
Diagnostics segment. Sales of investments in 2013 were used to provide cash to redeem all of the $300.0 million
8.0% Senior Subordinated Notes.

Effective tax rate

Our effective tax rate was 32%, 31% and 28% in 2014, 2013 and 2012, respectively. The effective tax rates for
2014 and 2013 are approximately the same. The effective tax rate for 2014 includes a lower tax benefit of research
tax credits because the effective tax rate for 2013 included a significant tax benefit related to the 2012 U.S. federal
research credit, which was retroactively reinstated on January 2, 2013. The additional tax benefit of research credits
in 2013 was offset by an increase in tax liabilities for unrecognized tax benefits and audit settlements in our foreign
jurisdictions.

The effective tax rates for all three periods were lower than the U.S. statutory rate primarily due to tax benefits from
differences between U.S. and foreign statutory tax rates, and research and development tax credits. Our foreign
income is earned primarily in Switzerland and France. Jurisdictions in which we operate that have statutory tax
rates that are significantly lower than the U.S. statutory tax rate of 35% include Switzerland, Russia, the U.K. and
Singapore.

Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but
not limited to, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and
generation of tax credits.

Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the
markets in which we trade. Goods are manufactured in a small number of locations, and are then shipped to local
distribution facilities around the world. Our product mix is diversified, and certain products compete largely on
product efficacy, while others compete on price. Gross margins are generally sufficient to exceed normal operating
costs, and funding for research and development of new products, as well as routine outflows of capital
expenditures, interest and taxes. In addition to the annual positive cash flow from operating activities, additional
liquidity is readily available via the sale of short-term investments and access to our $200.0 million unsecured
Credit Agreement that we entered into in June 2014. Borrowings under the Credit Agreement are on a revolving
basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes.
We had no outstanding borrowings under the Credit Agreement as of December 31, 2014, however $5.0 million was
utilized for domestic standby letters of credit that reduced our borrowing availability. The Credit Agreement
matures in June 2019.

At December 31, 2014, we had available $697.6 million in cash, cash equivalents and short-term investments, of
which approximately 43% was held in our foreign subsidiaries. We believe that our holdings of cash, cash
equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the
current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate
due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as
business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of
domestic and foreign cash flows (both inflows and outflows). Repatriation of overseas funds will result in
additional U.S. federal and state income tax payments. In general, it is our practice and intention to indefinitely
reinvest the cash generated by our foreign subsidiaries in our foreign subsidiaries' operations.

Under domestic and international lines of credit, we had $233.3 million available for borrowing as of December 31,
2014, which was reduced by $7.6 million that was utilized for standby letters of credit issued by our banks to
support our obligations, mostly to meet the deductible amount under insurance policies for our benefit.
Management believes that this availability, together with cash flow from operations, will be adequate to meet our
current objectives for operations, research and development, capital additions for manufacturing and distribution,
plant and equipment, information technology systems and an acquisition of reasonable proportion to our existing
total available capital.

While economic growth is somewhat improving, instability still exists in developed nations and in the U.S., which
may adversely affect our future results of cash flows. Demand for our products and services could change more
dramatically than in previous years based on activity, funding, reimbursement constraints and support levels from
government, universities, hospitals and private industry, including diagnostic laboratories. The need for certain
sovereign nations with large annual deficits to curtail spending could lead to slower growth of, or even a decline in,
our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could
impact our liquidity. The situation in these sovereign nations is continuously evolving and we have no greater
knowledge of the situation other than what is publicly reported. As of December 31, 2014 and December 31, 2013,
we had accounts receivable, net of allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of
$45.4 million and $66.0 million, respectively. Approximately $12.0 million of the decrease from December 31,
2013 was from currency, in addition to customer payments, most notably from Spain of approximately $11 million
from public agencies in the first quarter of 2014.

Cash Flows from Operations

Net cash provided by operations was $273.3 million, $169.1 million and $266.5 million in 2014, 2013, and 2012,
respectively. The net increase between 2014 and 2013 of $104.2 million primarily resulted from:

•

•
•

higher cash received from customers primarily due to improved collections, in particular from Spain of
approximately $11 million from public agencies in the first quarter of 2014, and in the U.S. after
implementing the first phase of a new ERP system,
a decrease in income taxes paid primarily due to a federal income tax quick refund of $20 million and a
French income tax refund of approximately $11 million that were both related to 2013 and received in 2014,
and a $5 million federal income tax extension payment in 2013,
the absence of interest paid of $25.0 million and $12.0 million in 2013 associated with a call premium
primarily due to the early redemption of the $300.0 million of 8.0% Senior Subordinated Notes on September
30, 2013,
a settlement payment for a royalties audit of $12 million in the second quarter of 2013, partially offset by
a payment of $55.1 million for the settlement with the SEC and DOJ associated with the FCPA.

The net decrease between 2013 and 2012 of $97.3 million primarily resulted from:

•
•

higher cash paid to employees, mostly due to an increase in headcount that included acquisitions,
an increase in outside services as we placed in service during the second quarter of 2013 the first phase of a
global single instance Enterprise Resource Planning (ERP) platform, moving to expense in the post-
implementation/operation stage from capitalizing in the application development stage in the prior year
period,
2012 benefited from an approximately $21 million payment for multiple years of Spanish receivables,
an increase in interest paid primarily due to the early redemption of the $300.0 million of 8.0% Senior
Subordinated Notes on September 30, 2013, and
a payment settlement for a royalties audit of $12 million in the second quarter of 2013,
partially offset by lower income tax payments and higher customer receipts.

We regularly review past due receivables to assess the allowance for doubtful accounts and believe net accounts
receivable are fully realizable. We also routinely review inventory for the impact of obsolescence and changes in
market prices caused by the introduction of new products, technologies and in government reimbursement policies.
We expect the first quarter of 2015 cash flows from operations to be lower than the fourth quarter of 2014 as Bio-Rad
historically has made larger payments for royalties, fourth quarter sales commissions to third parties and annual
employee bonuses during this period.

Cash Flows from Investing Activities

Net cash used in investing activities was $190.5 million and $400.4 million for 2014 and 2012, respectively, and net
cash provided by investing activities was $0.9 million in 2013. Purchases of marketable securities and investments,
and proceeds from sales of marketable securities and investments were both lower in 2014 than 2013 primarily due to
sales of securities to provide cash to redeem the $300.0 million 8.0% Senior Subordinated Notes. We therefore
expected purchases to decline markedly year over year due to reduced amounts of cash to invest. In addition, we
purchased longer dated securities to take advantage of higher returns on investments and therefore we experienced an
additional decline in maturities and redemptions of securities. Purchases for marketable securities and investments in
2013 were lower than 2012 primarily due to reallocating funds. Proceeds from the sale of marketable securities and
investments was higher in 2013 than 2012 primarily to provide cash to redeem all of the $300.0 million 8.0% Senior
Subordinated Notes.

Our investment objective is to maintain liquidity to meet anticipated operational and other corporate requirements in
which capital is preserved and increased through investing in low risk, high quality securities with commensurate
returns, consistent with our risk tolerance level.

Purchases of intangible assets were higher in 2014 than in 2013 and 2012 primarily due to the purchases of licenses.
Payments for acquisitions, net of cash received, and long-term investments in 2014, 2013 and 2012 were primarily
due to the following:

•

in April 2014, we acquired 100% of the issued and outstanding stock of GnuBIO for a total consideration of
$50.4 million, which includes $39.7 million paid in cash at the closing date and $10.7 million in contingent
consideration potentially payable to GnuBIO's shareholders,
in January 2013, we acquired 100% of the outstanding shares of AbD Serotec, a division of MorphoSys AG,
for total consideration of $62.2 million (net of cash received of $7.3 million),
in August 2012, we acquired from Propel Labs, Inc. a new cell sorting system that included $5.0 million in
cash at the closing date,
in July 2012, we acquired all of the outstanding shares of DiaMed Benelux for 4.6 million Euros
(approximately $5.6 million) in cash, and
in January 2012, we purchased, for cash, certain assets from a raw material supplier for approximately $12.5
million.

We continue to review possible acquisitions to expand both our Life Science and Clinical Diagnostics segments. We
routinely meet with the principals or brokers of the subject companies. It is not certain at this time that any of these
discussions involving material or significant acquisitions will advance to completion.

Capital expenditures in 2014 totaled $121.0 million, compared to $106.7 million and $142.9 million in 2013 and
2012, respectively. Capital expenditures represent the addition and replacement of production machinery and
research equipment, ongoing manufacturing and facility additions for expansion, regulatory, environmental and
compliance. Also included in capital expenditures are investments in business systems and data communication
upgrades and enhancements. All periods include equipment placed with Clinical Diagnostics segment customers who
then contract to purchase our reagents for use. Capital expenditures were higher in 2014 and 2012 as we were in the
development stages (in which costs are capitalized) of implementing the second and first phases, respectively, of a
global single instance ERP platform. In April 2013, we implemented the first phase of the global single instance ERP
platform and hence for the remainder of 2013, costs were no longer capitalized. As we continue to implement more
phases of the ERP platform and expand our e-commerce platform, we expect capital expenditures to continue to
remain historically higher for the next four years or more. The current estimated global implementation cost for the
single instance ERP platform will exceed $300 million and is estimated to take approximately four or more years to
fully implement.

Capital expenditures were lower in 2013 than in 2012 as we placed in service the first phase of a global single
instance ERP platform in 2013. During 2012 we were largely capitalizing development costs throughout the year.

Cash Flows from Financing Activities

Net cash provided by financing activities was $11.7 million and $12.6 million in 2014 and 2012, respectively, and net
cash used in financing activities was $311.7 million in 2013. Net cash provided by financing activities in 2014 was
primarily from proceeds from issuance of our common stock. Net cash provided by financing activities in 2014 was
partially offset by a payment of $2.4 million to Propel Labs' shareholders in contingent consideration for a sales
milestone that was associated with the valuation as of the 2012 acquisition date, and the payment of a short-term
borrowing. Net cash used in financing activities in 2013 was primarily due to the early redemption of the $300.0
million of 8.0% Senior Subordinated Notes on September 30, 2013. Also in 2013, $20.0 million was paid to Propel
Labs' shareholders in contingent consideration, of which $19.9 million was associated with the valuation as of the
2012 acquisition date and the remainder was recognized in cash flows from operations. Additionally in 2013, $6.0
million was paid to QuantaLife in contingent consideration, of which $5.6 million was associated with the valuation
as of the 2011 acquisition date and the remainder was recognized in cash flows from operations. Net cash provided in
2012 was primarily from proceeds from issuance of our common stock.

We have outstanding Senior Notes of $425.0 million, which are not due until 2020. As indicated above, we redeemed
all of the Senior Subordinated Notes of $300 million on September 30, 2013. We believe the current cash is sufficient
to meet normal operating costs, and funding for research and development of new products, as well as routine
outflows of capital expenditures, interest and taxes.

The Board of Directors has authorized the repurchase of up to $18.0 million of Bio-Rad's common stock, of which
$3.3 million has yet to be repurchased as of December 31, 2014. The Credit Agreement may limit our ability to
repurchase our stock. In accordance with the terms of awards under the 2007 Incentive Award Plan, in June 2012, we
withheld 122 shares of our Class A common stock and 917 shares of our Class B common stock to satisfy tax
obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of
our stock. All of the restricted stock vested as of December 31, 2013 and therefore we do not anticipate any
repurchasing of shares for this purpose. We had no other repurchases of our stock during 2014, 2013 or 2012.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have had or are reasonably likely to have a current or future
material effect on our financial condition, results of operations or liquidity.

Contractual Obligations

The following summarizes certain of our contractual obligations as of December 31, 2014 and the effect such
obligations are expected to have on our cash flows in future periods (in millions):

Contractual Obligations
Long-term debt, including
current portion (1)
Interest payments (1)
Operating lease obligations (2)
Purchase obligations (3)
Long-term liabilities (4)

Payments Due by Period

Less
Than
One Year

Total

1-3
Years

3-5
Years

More
than
5 Years

437.5
123.0
153.8
36.3
110.5

0.3
20.7
39.3
17.6
18.4

0.5
41.4
59.3
7.0
22.4

0.5 $

41.4
32.5
8.6
5.8

436.2
19.5
22.7
3.1
63.9

(1) These amounts represent expected cash payments, including capital lease obligations and notes payable, which are included in our
December 31, 2014 Consolidated Balance Sheet. Our debt is fixed and primarily consists of the 4.875% Notes. See Note 5 of the Consolidated
Financial Statements for additional information about our debt.

(2) Operating lease obligations are described in Note 12 of the Consolidated Financial Statements.

(3) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify
all significant terms. Purchase obligations exclude agreements that are cancelable without penalty.

(4) Excluded from this table are tax liabilities for uncertain tax positions and contingencies in the amount of $15.5 million. We are not able to
reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded from the table
above. See Note 6 of the Consolidated Financial Statements for additional information about our income taxes.

ITEM 7A. QUANTITIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Financial Risk Management

The main goal of Bio-Rad’s financial risk management program is to reduce the variance in expected cash flows
arising from unexpected foreign exchange rate and interest rate changes. Financial exposures are managed through
operational means and by using various financial instruments, including cash and liquid resources, borrowings, and
forward and spot foreign exchange contracts. No derivative financial instruments are entered into for the purpose of
trading or speculation. Company policy requires that all derivative positions are undertaken to manage the risks
arising from underlying business activities. These derivative transactions do not qualify for hedge accounting
treatment. Derivative instruments used in these transactions are valued at fair value and changes in fair value are
included in reported earnings.

Foreign Exchange Risk. We operate and conduct business in many countries and are exposed to movements in
foreign currency exchange rates. We face transactional currency exposures that arise when we enter into
transactions denominated in currencies other than U.S. dollars. Additionally, our consolidated net equity is
impacted by the conversion of the net assets of our international subsidiaries for which the functional currency is
not the U.S. dollar.

Foreign currency exposures are managed on a centralized basis. This allows for the netting of natural offsets and
lowers transaction costs and net exposures. Where possible, we seek to manage our foreign exchange risk in part
through operational means, including matching same-currency revenues to same-currency costs, and same-currency
assets to same-currency liabilities. Moreover, weakening in one currency can often be offset by strengthening in
another currency. Foreign exchange risk is also managed through the use of forward foreign exchange contracts.
Positions are primarily in Euro, Swiss Franc, British Sterling, Singapore Dollar, Brazilian Real and Japanese Yen.
The majority of forward contracts are for periods of 90 days or less. We record the change in value of our foreign
currency receivables and payables as a Foreign exchange (gain) loss on our Consolidated Statements of Income

along with the change in fair market value of the forward exchange contract used as an economic hedge of those
assets or liabilities.

Our forward contract holdings at year-end were analyzed to determine their sensitivity to fluctuations in foreign
currency exchange rates. All other variables were held constant. Market risk associated with derivative holdings is
the potential change in fair value of derivative positions arising from an adverse movement in foreign exchange
rates. A decline of 10% on quoted foreign exchange rates would result in an approximate net-present-value loss of
$32 million on our derivative position as of December 31, 2014. This impact of a change in exchange rates
excludes the offset derived from the change in value of the underlying assets and liabilities, which could reduce the
adverse effect significantly.

Interest Rate Risk of Debt Instruments. Bio-Rad centrally manages the short-term cash surpluses and shortfalls of
its subsidiaries. Our holdings of variable rate debt instruments at year-end were analyzed to determine their
sensitivity to movements in interest rates. Due to the relatively small amount of short-term variable rate debt we
have outstanding, there would not be a material impact to earnings or cash flows if interest rates moved adversely
by 10%. Our long-term debt consists primarily of fixed-rate instruments, and is thus insulated from interest rate
changes. As of December 31, 2014, the overall interest rate risk associated with our debt was not significant.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Index to Consolidated Financial Statements

Reports of Independent Registered Public Accounting Firms
Consolidated Balance Sheets at December 31, 2014 and 2013
Consolidated Statements of Income for each of the three years in the period ended

December 31, 2014

Consolidated Statements of Comprehensive Income for each of the three years in the period

December 31, 2014

Consolidated Statements of Cash Flows for each of the three years in the period ended

December 31, 2014

Consolidated Statements of Changes in Stockholders’ Equity for each of the three years

in the period ended December 31, 2014
Notes to Consolidated Financial Statements

Page

39-41
42-43

47
48-81

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders
Bio-Rad Laboratories, Inc.:

We have audited the accompanying consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries (the
Company) as of December 31, 2014 and 2013, and the related consolidated statements of income, comprehensive
income, stockholders’ equity, and cash flows for each of the years in the
period ended December 31, 2014.
In connection with our audits of the consolidated financial statements, we also have audited the financial statement
schedule. These consolidated financial statements and financial statement schedule are the responsibility of the
Company’s management. Our responsibility is to express an opinion on these consolidated financial statements and
financial statement schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United
States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the
financial position of Bio-Rad Laboratories, Inc. and subsidiaries as of December 31, 2014 and 2013, and the results
of their operations and their cash flows for each of the years in the
period ended December 31, 2014, in
conformity with U.S. generally accepted accounting principles. Also in our opinion, the related financial statement
schedule, when considered in relation to the basic consolidated financial statements taken as a whole, present fairly,
in all material respects, the information set forth therein.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States), Bio-Rad Laboratories, Inc.’s internal control over financial reporting as of December 31, 2014, based on criteria
established in Internal Control - Integrated Framework (1992) issued by the Committee of Sponsoring Organizations
of the Treadway Commission (COSO), and our report dated March 2, 2015 expressed an unqualified opinion on the
effectiveness of the Company’s internal control over financial reporting.

/s/ KPMG LLP

San Francisco, California
March 2, 2015

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders

Laboratories, Inc.:

We have audited Bio-Rad Laboratories, Inc.’s (the Company) internal control over financial reporting as of December
31, 2014, based on criteria established in Internal Control - Integrated Framework (1992) issued by the Committee
of Sponsoring Organizations of the Treadway Commission (COSO). Bio-Rad Laboratories Inc.’s management is
responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness
of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control
Over Financial Reporting (Item 9A(b)). Our responsibility is to express an opinion on the Company’s internal control
over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United
States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining
an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and
testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit
also included performing such other procedures as we considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles. A company’s internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on
the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may
deteriorate.

In our opinion, Bio-Rad Laboratories, Inc. maintained, in all material respects, effective internal control over financial
reporting as of December 31, 2014, based on criteria established in Internal Control - Integrated Framework (1992)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States), the consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries as of December 31, 2014 and
2013, and the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash
flows for each of the years in the two-year period ended December 31, 2014, and our report dated March 2, 2015
expressed an unqualified opinion on those consolidated financial statements and financial statement schedule.

/s/ KPMG LLP

San Francisco, California
March 2, 2015

Report of Ernst & Young LLP - Independent Registered Public Accounting Firm

The Board of Directors and Stockholders of Bio-Rad Laboratories, Inc.

We have audited the accompanying consolidated statements of income, comprehensive income, cash flows, and
changes in stockholders' equity of Bio-Rad Laboratories, Inc. for the year ended December 31, 2012. Our audit
also included the financial statement schedule listed in the Index at Item 15(a)2. These financial statements and
schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these
financial statements and schedule based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated
results of operations and cash flows of Bio-Rad Laboratories, Inc. for the year ended December 31, 2012, in
conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement
schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all
material respects the information set forth therein.

Redwood City, California
March 18, 2013, except for the section in Note 1 entitled ‘Correction of Immaterial Errors’, as to which the date is
March 2, 2015

/s/ Ernst & Young LLP

BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(In thousands)

ASSETS
Current assets:

Cash and cash equivalents
Short-term investments
Accounts receivable, less allowance for doubtful accounts of $27,973 at 2014 and

$32,471 at 2013

Inventories:

Raw materials
Work in process
Finished goods

Total inventories

Prepaid expenses
Other current assets
Total current assets

Property, plant and equipment:
Land and improvements
Buildings and leasehold improvements
Equipment
Total property, plant and equipment
Less: accumulated depreciation and amortization

Property, plant and equipment, net

Goodwill, net
Purchased intangibles, net
Other investments
Other assets

Total assets

December 31,

2014

2013

413,251
284,384

331,551
277,369

377,640

422,660

106,028
131,783
233,186
470,997

105,708
129,894
280,643
516,245

108,348
61,747
1,716,367

130,637
79,017
1,757,479

18,165
282,792
788,141
1,089,098
(660,262)
428,836

19,066
284,299
756,463
1,059,828
(645,427)
414,401

500,441
254,228
389,309
52,097
3,341,278

517,770
266,188
377,870
55,082
3,388,790

The accompanying notes are an integral part of these consolidated financial statements.

BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(continued)
(In thousands, except share data)

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued payroll and employee benefits
Notes payable and current maturities of long-term debt
Income and other taxes payable
Deferred revenue
Accrued legal settlements
Other current liabilities

Total current liabilities

Long-term debt, net of current maturities
Deferred income taxes
Other long-term liabilities
Total liabilities

Commitments and contingent liabilities

Stockholders’ equity:

Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and

outstanding - none

Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares

issued - 23,971,808 and 23,680,749 at 2014 and 2013, respectively; shares
outstanding - 23,971,686 and 23,680,627 at 2014 and 2013, respectively

Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares

issued - 5,098,799 and 5,096,780 at 2014 and 2013, respectively; shares
outstanding - 5,097,882 and 5,095,863 at 2014 and 2013, respectively

Additional paid-in capital

Class A treasury stock at cost, 122 shares at 2014 and 2013
Class B treasury stock at cost, 917 shares at 2014 and 2013

Retained earnings
Accumulated other comprehensive income

Total stockholders’ equity
Total liabilities and stockholders’ equity

December 31,

2014

2013

128,608
153,426
265
35,165
26,716
—
102,581
446,761

148,510
130,658
1,786
33,555
26,390
30,000
116,573
487,472

435,710
154,917
118,735
1,156,123

435,615
162,110
116,871
1,202,068

—

1
271,346
(12)
(89)
1,694,962
218,945
2,185,155
3,341,278

1
239,986
(12)
(89)
1,606,117
340,717
2,186,722
3,388,790

The accompanying notes are an integral part of these consolidated financial statements.

BIO-RAD LABORATORIES, INC.
Consolidated Statements of Income
(In thousands, except per share data)

Net sales

Cost of goods sold

Gross profit

Selling, general and administrative expense
Research and development expense

Income from operations
Interest expense
Foreign exchange losses, net
Other (income) expense, net

Income before income taxes

Provision for income taxes

Net income including noncontrolling interests

Net income attributable to noncontrolling interests

Net income attributable to Bio-Rad

Basic earnings per share:

Net income per basic share attributable to Bio-Rad
Weighted average common shares - basic

Diluted earnings per share:

Net income per diluted share attributable to Bio-Rad
Weighted average common shares - diluted

Year Ended December 31,

2014

2013

2012

2,175,044 $
996,527
1,178,517
808,200
220,333
149,984
22,131
9,305
(13,009)
131,557
(42,712)
88,845
—
88,845 $

2,132,694 $
954,216
1,178,478
798,070
210,952
169,456
61,271
8,566
(12,766)
112,385
(34,574)
77,811
(21)
77,790 $

2,069,235
914,077
1,155,158
681,778
209,204
264,176
51,112
5,040
(21,883)
229,907
(64,361)
165,546
(69)
165,477

3.08 $

2.72 $

28,876

28,586

5.85
28,290

3.05 $

2.69 $

29,133

28,906

5.78
28,642

The accompanying notes are an integral part of these consolidated financial statements.

BIO-RAD LABORATORIES, INC.
Consolidated Statements of Comprehensive Income
(In thousands)

Net income including noncontrolling interests
Other comprehensive income:

Foreign currency translation adjustments

Foreign other post-employment benefits adjustments, net of
income taxes
Net unrealized holding gains on available-for-sale (AFS)
investments, net of income taxes

Other comprehensive (loss) income, net of income taxes
Comprehensive (loss) income

Comprehensive income attributable to noncontrolling
interests

Comprehensive (loss) income attributable to Bio-Rad

Year Ended December 31,
2013

2014

88,845

77,811 $

2012
165,546

(118,142)

16,662

23,738

(8,186)

(8,278)

4,556
(121,772)
(32,927)

49,651
66,349
144,160

60,403
75,863
241,409

—
(32,927) $

(185)
143,975 $

(90)
241,319

Reclassification adjustments are calculated using the specific identification method.
The accompanying notes are an integral part of these consolidated financial statements.

BIO-RAD LABORATORIES, INC.
Consolidated Statements of Cash Flows
(In thousands)

Cash flows from operating activities:
Cash received from customers
Cash paid to suppliers and employees
Interest paid
Income tax payments
Settlement with the SEC and DOJ relating to the FCPA, including
interest
Investment proceeds and miscellaneous receipts, net
Excess tax benefits from share-based compensation
Proceeds from (payments for) forward foreign exchange contracts, net
Net cash provided by operating activities

Cash flows from investing activities:

Capital expenditures
Proceeds from dispositions of property, plant and equipment
Payments for acquisitions, net of cash received, and long-term
investments
Payments for purchases of intangible assets
Payments for purchases of marketable securities and investments
Proceeds from sales of marketable securities and investments
Proceeds from maturities of marketable securities and investments
Net cash (used in) provided by investing activities

Cash flows from financing activities:

Net (payments) borrowings on line-of-credit arrangements and notes
payable
Payments on long-term borrowings
Proceeds from issuance of common stock
Payments of contingent consideration
Debt issuance costs on long-term borrowings
Purchase of treasury stock
Excess tax benefits from share-based compensation
Net cash provided by (used in) financing activities

Effect of foreign exchange rate changes on cash
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year

Year Ended December 31,
2012

2013

2014

$ 2,162,520
(1,806,526)
(20,793)
(28,939)

$2,090,030
(1,804,028)
(61,233)
(71,144)

$ 2,063,805
(1,664,491)
(46,369)
(93,697)

(55,050)
15,671
(1,349)
7,778
273,312

—
16,760
(2,720)
1,471
169,136

—
12,991
(2,889)
(2,870)
266,480

(120,999)
225

(106,658)
1,214

(142,869)
6,325

(44,627)
(15,479)
(205,746)
75,725
120,390
(190,511)

(72,054)
(700)
(386,714)
289,779
276,052
919

(39,443)
(1,780)
(680,966)
131,295
327,052
(400,386)

(1,560)
(253)
15,051
(2,374)
(524)
—
1,349
11,689
(12,790)
81,700
331,551
$ 413,251

48
(300,228)
11,237
(25,474)
—
—
2,720
(311,697)
9,805
(131,837)
463,388
$ 331,551

(191)
(620)
10,611
—
—
(101)
2,889
12,588
10,475
(110,843)
574,231
$ 463,388

The accompanying notes are an integral part of these consolidated financial statements.

BIO-RAD LABORATORIES, INC.
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands)

Common
Stock

Additional
Paid-in
Capital

Treasury
Stock

Retained
Earnings

Accumulated
Other
Comprehensive
Income

Total
Bio-Rad
Stockholders'
Equity

Non-
controlling
Interests

Total
Stockholders'
Equity

Balance at December 31, 2011
Net income
Other comprehensive income, net
of tax
Issuance of common stock
Stock compensation expense
Tax benefit-exercise stock options
Purchase of treasury stock
Balance at December 31, 2012
Net income
Other comprehensive income, net
of tax
Issuance of common stock
Stock compensation expense
Tax benefit-exercise stock options
Purchase of additional controlling
interests and other
Balance at December 31, 2013
Net income
Other comprehensive loss, net of
tax
Issuance of common stock
Stock compensation expense
Tax benefit-exercise stock options

3
—

—
—
—
—
—
3
—

—
—
—
—

—
3
—

—
—
—
—

$ 185,334
—

$ — $ 1,362,850
165,477

—

$ 198,690
—

$ 1,746,877
165,477

—
10,611
12,936
3,363

—
—
—
—
— (101)
(101)
—

212,244
—

—
11,237
13,657
3,135

—
—
—
—

—
—
—
—
—
1,528,327
77,790

—
—
—
—

75,842
—
—
—
—
274,532
—

66,185
—
—
—

75,842
10,611
12,936
3,363
(101)
2,015,005
77,790

66,185
11,237
13,657
3,135

445
69

21
—
—
—
—
535
21

164
—
—
—

$ 1,747,322
165,546

75,863
10,611
12,936
3,363
(101)
2,015,540
77,811

66,349
11,237
13,657
3,135

(287)
239,986
—

—
(101)
—

—
1,606,117
88,845

—
340,717
—

(287)
2,186,722
88,845

(720)
—
—

(1,007)
2,186,722
88,845

—
15,051
14,888
1,421

—
—
—
—

— (121,772)
—
—
—
—
—
—

(121,772)
15,051
14,888
1,421

—
—
—
—

(121,772)
15,051
14,888
1,421

Balance at December 31, 2014

$ 271,346

$ (101) $ 1,694,962

$ 218,945

$ 2,185,155

$ — $ 2,185,155

The accompanying notes are an integral part of these consolidated financial statements.

BIO-RAD LABORATORIES, INC.
Notes to Consolidated Financial Statements

SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and
majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of
intercompany balances and transactions. The preparation of financial statements in conformity with U.S. generally
accepted accounting principles requires management to make estimates and assumptions that affect the amounts
reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance
sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are
issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements.
Events and conditions arising after the balance sheet date but before the financial statements are issued are
evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the
extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated
financial effects for those events and conditions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or
less which are readily convertible into cash. Cash equivalents are stated at cost, which approximates fair value.

Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S.
government sponsored agencies and marketable equity securities. Management classifies investments at the time of
purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one
year may be classified as short-term based on their liquid nature and because such marketable securities represent
the investment of cash that is available for current operations. Available-for-sale investments are reported at fair
value based on quoted market prices and other observable market data. Unrealized gains and losses are reported as
a component of other comprehensive income, net of any related tax effect. Unrealized losses are charged against
income when a decline in the fair value of an individual security is determined to be other-than-temporary. We
review our available-for-sale investments for other-than-temporary losses on a quarterly basis. Realized gains and
losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note
10).

Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash
equivalents, investments, foreign exchange contracts and trade accounts receivable. Cash and cash equivalents and
investments are placed with various highly rated major financial institutions located in different geographic regions.
Bio-Rad has not sustained significant losses from instruments held at financial institutions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the
counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the
counterparties to a diverse group of highly-rated domestic and international financial institutions. In the event of
non-performance by these counterparties, the carrying values of our financial instruments represent the maximum

amount of loss we would have incurred as of our fiscal year-end. However, we do not expect to record any losses
as a result of counterparty default.

We perform credit evaluation procedures related to our trade receivables and with the exception of certain
developing countries, generally do not require collateral. As a result of increased risk in certain developing
countries, some Bio-Rad sales are subject to collateral letters of credit from our customers. Credit risk for trade
accounts receivable is generally limited due to the large number of customers and their dispersion across many
geographic areas. However, a significant amount of trade receivables are with national healthcare systems in
countries within the European Union.

Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to
make required payments. The amount of the allowance is determined by analyzing known uncollectible accounts,
aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’
credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written
off against this allowance.

Inventory

Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and
overhead costs. The first-in, first-out method is used to relieve inventory for products sold.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization. Included in
property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent
rental equipment and capitalized software, including costs for software developed or obtained for internal use.
Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in
circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. Buildings and
leasehold improvements are amortized over 15-30 years or the term of the leases or life of the improvements,
whichever is shorter. With the exception of reagent rental equipment, which is amortized over a 1-5 year period,
equipment and capitalized software is depreciated over 3-12 years.

Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of
acquired businesses. Goodwill is assessed for impairment by applying fair value based tests annually in the fourth
quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating
segments. Our reporting units are identified as components for which discrete financial information is available and
is regularly reviewed by management. Goodwill amounts are assigned to reporting units at the time of acquisition.

The goodwill impairment test consists of a two-step process. The first step of the goodwill impairment test, used to
identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill.
We use a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of
the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the
second step of the impairment test is not required. The second step, if required, compares the implied fair value of
the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated
to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit
had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire

the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an
impairment charge is recognized in an amount equal to that excess.

Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with
other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash
flows of other assets and liabilities. We assess the impairment of long-lived assets (including identifiable intangible
assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be
recoverable. Factors that we consider important that could trigger an impairment review include:

•
•

•

significant under-performance relative to expected, historical or projected future operating results;
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our
overall business;
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a
loss before the end of its previously estimated useful life; and
significant negative industry, legal, regulatory or economic trends.

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax
assets and liabilities for the expected future tax consequences of events that have been included in the financial
statements. Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and
temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the
amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which
the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is
recognized in income in the period that includes the enactment date.

We record deferred tax assets to the extent we believe these assets will more likely than not be realized. In making
such determination, we consider all available positive and negative evidence, including scheduled reversals of
deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To
the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net
recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income
taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for
income taxes will increase or decrease, respectively, in the period that determination to change the valuation
allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position
will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax
benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit
that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax
benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to
existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax
examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate,
related to unrecognized tax benefits in the provision for income taxes.

Revenue Recognition

Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or
determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered
absent specific contractual specifications. Revenue associated with equipment that requires factory installation is
not recorded until installation is complete and customer acceptance, if required contractually, has occurred. At the
time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended
warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not
under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer
(sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.

Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables
(reagents) to a customer on a per test basis. We evaluate our reagent agreements and account for these contracts
under the guidance pertaining to accounting for revenue arrangements with multiple deliverables. Our reagent
agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a
diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn
under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely
contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) as reported
by the customer on a per test basis.

Shipping and Handling

We classify all freight costs billed to customers as Net sales. Related freight costs are included in Cost of goods
sold.

Warranty

We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one
year. Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected
costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is
performed on a quarterly basis to assess the adequacy of our warranty accrual.

Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as
follows (in millions):

January 1

Provision for warranty
Actual warranty costs

December 31

Research and Development

2014

2013

15.6 $
28.6
(26.4)
17.8 $

16.4
15.6
(16.4)
15.6

Internal research and development costs are expensed as incurred. Third-party research and development costs are
expensed when the contracted work has been performed.

Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each
accounting period. Income statement items are translated at average exchange rates for the period. The resulting
translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated
Statements of Income. Transaction gains and losses result primarily from fluctuations in exchange rates when
intercompany receivables and payables are denominated in currencies other than the functional currency of our
subsidiary that recorded the transaction.

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward
foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect
foreign currency denominated intercompany receivables and payables. We do not use derivative financial
instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts.
As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in
currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance
sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all
of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.

Noncontrolling Interests

A noncontrolling interest in a subsidiary is an ownership interest in a consolidated entity that is reported as equity in
the consolidated financial statements and separate from Bio-Rad’s equity. In addition, net income attributable to
noncontrolling interests is reported separately from net income attributable to Bio-Rad in the consolidated financial
statements. Our consolidated statements presented the full amount of assets, liabilities, income and expenses of all
of our consolidated subsidiaries, with a partially offsetting amount shown in noncontrolling interests for the portion
of assets and liabilities that were not controlled by us.

In February 2013, we acquired the remaining outstanding shares of Distribuidora de Analitica para Medicina Iberica
S.A. (DiaMed Spain) from the remaining noncontrolling shareholder for approximately 0.6 million Euros or $0.9
million in cash. This acquisition was accounted for as an equity transaction, which reduced Bio-Rad's
noncontrolling interests and additional paid-in capital by $0.6 million and $0.3 million, respectively, and therefore
since that date there are no noncontrolling interests in Bio-Rad.

Share-Based Compensation Plans

Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-
date fair value. We recognize these compensation costs net of estimated forfeitures over the requisite service period
of the award, which is generally the vesting term of the share-based payment awards. We estimated the forfeiture
rate based on our historical experience. These plans are described more fully in Note 9.

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average
number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of
dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in
determining the number of potential common shares that are to be added to the weighted average number of shares
outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect
would be anti-dilutive.

Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents
(whether paid or unpaid) are participating securities and are included in the computation of earnings per share
(EPS) pursuant to the two-class method. As our unvested restricted shares qualify as participating securities, we
have included these shares in the computation of EPS.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share
and the anti-dilutive shares are as follows (in thousands):

Basic weighted average shares outstanding
Effect of potentially dilutive stock options
and restricted stock awards
Diluted weighted average common shares

Anti-dilutive stock options and restricted stock awards
excluded from the computation of diluted EPS

Fair Value of Financial Instruments

Year Ended December 31,
2013

2012

2014

28,876

28,586

28,290

257
29,133

320
28,906

352
28,642

122

107

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable,
marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts
approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset
or paid to transfer a liability (an exit price) using available market information or other appropriate valuation
methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants. Estimates are not necessarily indicative of the amounts that could be realized in a
current market exchange as considerable judgment is required in interpreting market data used to develop estimates
of fair value. The use of different market assumptions or estimation techniques could have a material effect on the
estimated fair value (see Note 3).

Correction of Immaterial Errors

Balance Sheet and Statement of Cash Flows

Management evaluated the materiality of the errors described above from a qualitative and quantitative perspective
in accordance with the requirements of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin
No. 99, Materiality (SAB 99). Based on such evaluation, we have concluded that while these errors were
significant to the periods impacted, their correction would not be material to any individual prior period nor did
they have an effect on financial results. Accordingly, we are correcting these errors in every affected period in our
Consolidated Financial Statements.

Recent Accounting Standards Updates

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of
revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09
will replace most existing revenue recognition guidance in U.S. Generally Accepted Accounting Principles when it
becomes effective. The new standard is effective for annual reporting periods beginning after December 15, 2016,
including interim periods within that reporting period and is to be applied retrospectively, with early application not
permitted. The new standard permits the use of either the retrospective or cumulative effect transition method. We
are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related
disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our
ongoing financial reporting.

ACQUISITIONS

GnuBIO, Inc.

In April 2014, we acquired 100.0% of the issued and outstanding stock of GnuBIO, Inc. (GnuBIO). This
acquisition was accounted for as a business combination as GnuBIO represents an integrated set of activities and
assets capable of being conducted and managed for the purpose of providing a return and therefore constitutes a
business in accordance with GAAP. The amount of acquisition-related costs was minimal as Bio-Rad primarily
represented itself during the acquisition process. This business acquisition is included in our Clinical Diagnostics
segment's results of operations from the acquisition date. We believe that GnuBIO's innovative DNA workflow is
well-suited for the clinical diagnostics sequencing market and will leverage our leadership role in the area of droplet
digital PCR.

The excess of purchase consideration over the fair value of net tangible and identifiable intangible assets acquired
was recorded as goodwill. The fair values assigned to tangible and identifiable intangible assets acquired and
liabilities assumed are based on management’s estimates and assumptions. During the fourth quarter of 2014, we
finalized the determination of fair values of certain acquired tax attributes and adjusted the preliminary carrying
values of goodwill and certain other assets and liabilities in order to reflect final information received and the
finalization of certain tax returns, resulting in an overall reduction to goodwill of $1.7 million. These measurement
period adjustments had no impact on our results of operations for the year ending December 31, 2014.

Accounting guidance requires that the fair value of IPR&D acquired in a business combination be recorded on the
balance sheet as of the acquisition date. Intangible assets related to IPR&D projects are considered to be indefinite-
lived until completion or abandonment of the related project. During the period the assets are considered indefinite-
lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if we
become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value
of the projects below their respective carrying amounts. We perform our annual impairment tests at December 31.

If and when it is determined that identified intangible assets are impaired, an impairment charge would be recorded.
If and when development is considered complete, the associated assets would be deemed finite-lived and would
then be amortized based on their respective remaining estimated useful lives.

The fair value of the consideration as of the acquisition date was $50.4 million, which includes $39.7 million paid
in cash at the closing date and $10.7 million in contingent consideration potentially payable to GnuBIO's
shareholders. The contingent consideration was based on a probability-weighted income approach that could reach
$70.0 million upon the achievement of all development/regulatory and sales milestones. The contingent
consideration for the development/regulatory milestones was valued at $10.7 million, based on assumptions
regarding the probability of achieving the milestones, with such amounts discounted to present value. The
contingent consideration for the sales milestones was determined to be negligible, using the risk-neutral probability
of being in the money based on a Black-Scholes framework. The contingent consideration was recognized at its
estimated fair value of $10.0 million as of December 31, 2014. See Note 3 for further discussion of the contingent
consideration valuation and underlying assumptions.

We do not consider this business combination to be material and therefore have not disclosed the pro forma results
of operations as required for material business combinations.

AbD Serotec

In January 2013, we acquired 100% of the outstanding shares of AbD Serotec, a division of MorphoSys AG, for
total consideration of $62.2 million (net of cash received of $7.3 million). This acquisition was accounted for as a
business combination as AbD Serotec represented an integrated set of activities and assets that was capable of being
conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance
with GAAP. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during
the acquisition process. This business acquisition is included in our Life Science segment's results of operations
from the acquisition date. We believe that with AbD Serotec's comprehensive catalog of antibodies, we are able to
offer our customers total assay solutions that can be validated on many of our research platforms for western
blotting, multiplex protein expression, ELISA and cell sorting.

During the second quarter of 2013, we finalized the determination of fair values of certain acquired intangible assets
and adjusted the preliminary carrying values of goodwill and certain other assets and liabilities to include final
information received, and an update to the weighted average tax rate applied to our valuation model and changes in
the determination of fair values of certain assets acquired and liabilities assumed. These factors that existed as of
the acquisition date resulted in an overall increase to intangible assets of $1.7 million, a reduction of goodwill of
$2.1 million and an increase to net tangible assets of $0.4 million. These measurement period adjustments did not
have a material impact on our previously reported condensed consolidated financial statements and, therefore, we
have not retrospectively adjusted those financial statements.

The final fair values of the net assets acquired consist of definite-lived intangible assets of $44.0 million, goodwill
of $14.9 million and net tangible assets of $3.3 million. A portion of the goodwill recorded is deductible for income
tax purposes.

3. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in
pricing the asset or liability in an orderly transaction between market participants at the measurement date. The
identification of market participant assumptions provides a basis for determining what inputs are to be used for
pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value
measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes
the inputs into three broad levels as follows:

• Level 1: Quoted prices in active markets for identical instruments
• Level 2: Other significant observable inputs (including quoted prices in active markets for similar

instruments)

• Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain

investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2014 are
classified in the hierarchy as follows (in millions):

Level 1

Level 2

Level 3

Total

Financial Assets Carried at Fair Value:
Cash equivalents (a):
Commercial paper
Foreign time deposits
Money market funds

Total cash equivalents
Available-for-sale investments (b):

Corporate debt securities
Foreign brokered certificates of deposit
U.S. government sponsored agencies
Foreign government obligations
Municipal obligations
Marketable equity securities
Asset-backed securities

Total available-for-sale investments

Forward foreign exchange contracts (c)

Total financial assets carried at fair value

Financial Liabilities Carried at Fair Value:
Forward foreign exchange contracts (d)
Contingent consideration (e)

Total financial liabilities carried at fair value

— $

16.5
2.2
18.7

—
—
—
—
—
334.4
—
334.4
—
353.1 $

4.0 $
—
—
4.0

139.9
5.2
47.5
4.0
6.5
—
48.4
251.5
0.6
256.1 $

— $
—
—
—

—
—
—
—
—
—
—
—
—
— $

— $
—
— $

1.7 $
—
1.7 $

— $

27.7
27.7 $

4.0
16.5
2.2
22.7

139.9
5.2
47.5
4.0
6.5
334.4
48.4
585.9
0.6
609.2

1.7
27.7
29.4

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2013 are
classified in the hierarchy as follows (in millions):

Financial Assets Carried at Fair Value:
Cash equivalents (a):
Commercial paper
Foreign time deposits
U.S. government sponsored agencies
Money market funds

Total cash equivalents
Available-for-sale investments (b):

Total available-for-sale investments

Forward foreign exchange contracts (c)

Total financial assets carried at fair value

Financial Liabilities Carried at Fair Value:
Forward foreign exchange contracts (d)
Contingent consideration (e)

Total financial liabilities carried at fair value

Level 1

Level 2

Level 3

Total

— $

11.1
—
1.2
12.3

—
—
—
—
—
325.2
—
325.2
—
337.5 $

7.0
—
1.2
—
8.2

132.5
8.9
39.1
5.6
11.0
—
48.6
245.7
0.6
254.5

— $
—
—
—
—

—
—
—
—
—
—
—
—
—
— $

— $
—
— $

1.1
—
1.1 $

— $

20.8
20.8 $

7.0
11.1
1.2
1.2
20.5

132.5
8.9
39.1
5.6
11.0
325.2
48.6
570.9
0.6
592.0

1.1
20.8
21.9

(a) Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b) Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets

(in millions):

Short-term investments
Other investments

Total

December 31,
2014

December 31,
2013

284.4
301.5
585.9

277.4
293.5
570.9

Consolidated Balance Sheets.

(d) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the

Consolidated Balance Sheets.

(e) Contingent consideration liabilities are included in the following accounts in the Consolidated Balance

Sheets (in millions):

Other current liabilities
Other long-term liabilities
Total

December 31,
2014

December 31,
2013

13.1
14.6
27.7

6.1
14.7
20.8

During the second quarter of 2014, we recognized a contingent consideration liability upon our acquisition of
GnuBIO. At the acquisition date, the contingent consideration was based on a probability-weighted income
approach that could reach $70.0 million upon the achievement of all development/regulatory and sales milestones.
The contingent consideration for the development/regulatory milestones was valued at $10.7 million at the
acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts
discounted to present value. During the fourth quarter of 2014, the contingent consideration related to the
development/regulatory milestones was revalued to a fair value of $10.0 million as of December 31, 2014. The
contingent consideration for the sales milestones at the acquisition date and at December 31, 2014 was determined
to be negligible, using the risk-neutral probability of being in the money based on a Black-Scholes framework.

The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at
estimated fair value based on original valuations and updated quarterly for the year ended December 31, 2014 (in
millions):

January 1
Cell sorting system:
Payment of sales milestone
Net decrease in estimated fair value of contingent
consideration included in Selling, general and
administrative expense
GnuBIO:
Acquisition of GnuBIO
Net decrease in estimated fair value of contingent
consideration included in Selling, general and
administrative expense
December 31

2014

20.8

(2.4)

(0.7)

10.7

(0.7)
27.7

The following table provides quantitative information about Level 3 inputs for fair value measurement of our
contingent consideration liabilities as of December 31, 2014. Significant increases or decreases in these inputs in
isolation could result in a significantly lower or higher fair value measurement.

Cell sorting
system

Valuation Technique
Probability-weighted
income approach

GnuBIO

Probability-weighted
income approach

Unobservable Input

Sales milestone:
Credit adjusted discount rates
Projected volatility of growth rates
Market price of risk

Range

From

0.62%
10.0%
1.75%

1.22%
N/A
N/A

Development/regulatory milestones:
Milestones probability
Discount rate

50.0%
0.34%

75.0%
0.48%

Sales milestones:
Milestones probability
Discount rate

—%
0.92%

N/A
2.04%

To estimate the fair value of Level 2 debt securities as of December 31, 2014 and 2013, our primary pricing
provider uses S&P Capital IQ as the primary pricing source. Our pricing process allows us to select a hierarchy of
pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of
deposit and commercial paper, is S&P Capital IQ as the primary pricing source and then our custodian as the
secondary pricing source. If S&P Capital IQ does not price a Level 2 security that we hold, then the pricing
provider will utilize our custodian supplied pricing.

For commercial paper as of December 31, 2014 and 2013, pricing is determined by a straight-line calculation,
starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing
certificates of deposit and commercial paper are priced at par.

In addition to the above, our primary pricing provider performed daily reasonableness testing of S&P Capital IQ
prices to custodian reported prices. Prices outside a tolerable variance of approximately 1% are investigated and
resolved.

Available-for-sale investments consist of the following (in millions):

Short-term investments:

Corporate debt securities
Foreign brokered certificates of deposit
Municipal obligations
Asset-backed securities
U.S. government sponsored agencies
Foreign government obligations
Marketable equity securities

Long-term investments:

Marketable equity securities
Asset-backed securities

Total

Short-term investments:

Long-term investments:

Marketable equity securities
Asset-backed securities

December 31, 2014

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Estimated
Fair
Value

139.7 $
5.2
6.5
48.2
47.4
4.0
29.0
280.0

54.5
0.4
54.9
334.9 $

0.4 $
—
—
—
0.1
—
4.5
5.0

246.6
—
246.6
251.6 $

(0.2) $
—
—
(0.2)
—
—
(0.2)
(0.6)

—
—
—
(0.6) $

139.9
5.2
6.5
48.0
47.5
4.0
33.3
284.4

301.1
0.4
301.5
585.9

December 31, 2013

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Estimated
Fair
Value

132.6 $
8.9
11.1
48.4
39.1
5.6
26.6
272.3

54.5
0.4
54.9

0.3 $
—
—
0.1
0.1
—
5.4
5.9

238.7
—
238.7

(0.4) $
—
(0.1)
(0.2)
(0.1)
—
—
(0.8)

—
(0.1)
(0.1)

132.5
8.9
11.0
48.3
39.1
5.6
32.0
277.4

293.2
0.3
293.5

570.9

Total

327.2 $

244.6 $

(0.9) $

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

December 31,
2014

December 31,
2013

Fair value of investments in a loss position 12 months or more
Fair value of investments in a loss position less than 12 months
Gross unrealized losses for investments in a loss position 12 months or more
Gross unrealized losses for investments in a loss position less than 12 months

$
$
$
$

8.4 $

90.7

0.2 $
0.4 $

2.3
73.9
0.1
0.8

The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes
in economic conditions and changes in market outlook for various industries, among others. Because Bio-Rad has
the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a
reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not
consider these investments to be other-than-temporarily impaired at December 31, 2014 or at December 31, 2013.

As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward
foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that
affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial
instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As
a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of
industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts
provide one measure of the transaction volume outstanding as of December 31, 2014 and do not represent the
amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates
from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains
or losses offset exchange gains or losses on the related receivables and payables, both of which are included in
Foreign exchange losses, net in the Consolidated Statements of Income.

The following is a summary of our forward foreign currency exchange contracts (in millions):

Contracts maturing in January through March 2015 to sell foreign currency:

Notional value
Unrealized loss

Contracts maturing in January through March 2015 to purchase foreign currency:

Notional value
Unrealized loss

December 31,
2014

$
$

81.1
1.0

285.8
0.2

The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31,
2014 by contractual maturity date (in millions):

Mature in less than one year
Mature in one to five years
Mature in more than five years

Total

Amortized
Cost

Estimated Fair
Value

110.7 $
99.9
40.8

251.4 $

110.7
99.9
40.9

251.5

The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance
Sheets and are included in Other investments, are presented in the table below. Fair value has been determined
using significant observable inputs, including quoted prices in active markets for similar instruments. Estimates
are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable
judgment is required in interpreting market data used to develop estimates of fair value. The use of different market
assumptions or estimation techniques could have a material effect on the estimated fair value. Other investments
include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted
for various discounts, including a discount for marketability. Long-term debt, excluding leases and current
maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within
which the fair value measurement is categorized are as follows (in millions):

December 31, 2014

December 31, 2013

Other investments
Total long-term debt, excluding leases

and current maturities

Carrying
Amount
$

82.6 $

Estimated
Fair
Value

401.1

Fair Value
Hierarchy
Level
2

Carrying
Amount
77.5
$

Estimated
Fair
Value
$

382.9

Fair Value
Hierarchy
Level
2

$ 423.5 $

454.9

423.2 $

433.0

We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology
supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over 35% of the
outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2014. The Sartorius family
trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any
representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant
influence over the operating and financial policies of Sartorius. We account for this investment using the cost
method. The carrying value of this investment is included in Other investments in our Consolidated Balance
Sheets. As the stock is thinly traded and in conjunction with the valuation method discussed above, we have
classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method
employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock.

GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):

Balances as of January 1:

Goodwill

Accumulated impairment losses and write-offs

Goodwill, net

Acquisitions

Currency fluctuations

Balances as of December 31:

Goodwill

Accumulated impairment losses and write-offs

2014

2013

Life
Science

Clinical
Diagnostics

Total

Life
Science

Clinical
Diagnostics

Total

209.0

337.0

$ 546.0

193.6

330.0

$ 523.6

(27.2)

181.8

—

(1.3)

207.7

(27.2)

(1.0)

(28.2)

336.0

13.5

517.8

13.5

(29.6)

(30.9)

320.9

(1.0)

528.6

(28.2)

(27.2)

166.4

14.9

0.5

209.0

(27.2)

(1.0)

329.0

—

7.0

337.0

(1.0)

(28.2)

495.4

14.9

7.5

546.0

(28.2)

Goodwill, net

180.5

319.9

$ 500.4

181.8

336.0

$ 517.8

In conjunction with the acquisition of 100% of the outstanding stock of GnuBIO, Inc. in our Clinical Diagnostics
segment in April 2014, we recorded $13.5 million of goodwill and $46.4 million of in-process research and
development, an indefinite-lived intangible asset.

In conjunction with the acquisition of 100% of the outstanding shares of AbD Serotec in our Life Science segment
in January 2013, we recorded $14.9 million of goodwill and $44.0 million of definite-lived intangible assets: $33.0
million of developed product technology, $8.8 million of licenses, $1.3 million of customer relationships/lists, $0.4
million of tradenames and $0.5 million of other purchased intangibles. The weighted average useful lives of the
definite-lived intangible assets as of the acquisition date were 13.9, 13, 12, 2 and 1 years, respectively, with a total
weighted average useful life of 13.7 years.

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in
millions):

Customer relationships/lists
Know how
Developed product technology
Licenses
Tradenames
Covenants not to compete
Total definite-lived intangible assets
In-process research and development
Total purchased intangible assets

Customer relationships/lists
Know how
Developed product technology
Licenses
Tradenames
Covenants not to compete
Other

Average
Remaining
Life (years)
3-10
1-11
5-12
1-11
1-10
3-8

Average
Remaining
Life (years)
1-11
2-12
1-13
1-12
1-9
5-9
—

December 31, 2014

Purchase
Price

Accumulated
Amortization

Net
Carrying
Amount

89.4 $
184.7
103.9
39.4
3.6
4.9
425.9
46.4
472.3 $

(43.0) $
(102.5)
(42.8)
(26.5)
(2.1)
(1.2)
(218.1)
—
(218.1) $

46.4
82.2
61.1
12.9
1.5
3.7
207.8
46.4
254.2

December 31, 2013

Purchase
Price

Accumulated
Amortization

Net
Carrying
Amount

99.8 $
194.6
109.5
44.9
4.3
4.9
0.6
458.6 $

(41.1) $
(89.3)
(36.2)
(22.4)
(2.1)
(0.7)
(0.6)
(192.4) $

58.7
105.3
73.3
22.5
2.2
4.2
—
266.2

No material impairment losses related to purchased intangible assets were recorded in 2013. In 2014, we impaired
licenses of a discontinued product line in the amount of $6.4 million. The impairment charge included $5.8 million
in Cost of goods sold and $0.6 million in Research and development expense in the accompanying Consolidated
Statements of Income.

Amortization expense related to purchased intangible assets for the years ended December 31, 2014, 2013 and 2012
was $47.8 million, $45.0 million and $42.8 million, respectively. Estimated future amortization expense (based on
existing purchased intangible assets, not including IPR&D) for the years ending December 31, 2015, 2016, 2017,
2018, 2019 and thereafter is $38.4 million, $35.5 million, $26.9 million, $23.5 million, $20.5 million, and $74.4
million, respectively.

NOTES PAYABLE AND LONG-TERM DEBT

Notes payable includes amounts borrowed against credit lines maintained locally by our international subsidiaries,
under which the borrowing capacity was approximately $40.9 million, of which $38.3 million was available for
borrowing at December 31, 2014. At December 31, 2013, borrowing capacity aggregated approximately $20.1
million, of which $15.8 million was available for borrowing. The weighted average interest rate on these lines was
1.4% and 3.0% at December 31, 2014 and 2013, respectively. Bio-Rad guaranteed 23 of these credit lines at
December 31, 2014 and eight at December 31, 2013.

The principal components of long-term debt are as follows (in millions):

4.875% Senior Notes due 2020, net of discount
Capital leases and other debt

Less current maturities
Long-term debt

Senior Subordinated Notes due 2016

December 31,
2014

December 31,
2013

423.5
12.5
436.0
(0.3)

435.7 $

423.2
12.6
435.8
(0.2)

435.6

In May 2009, Bio-Rad sold $300.0 million principal amount of Senior Subordinated Notes due 2016 (8.0% Notes).
The sale yielded net cash proceeds of $294.8 million. In September 2013, we redeemed all of the 8.0% Notes for
$312.0 million, including a call premium of $12.0 million, and expensed the remaining original issuance bond
discount of $2.5 million and unamortized bond issuance costs of $1.1 million. The total expense for the redemption
was $15.6 million and is included in Interest expense in our Consolidated Statements of Income.

Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 (4.875% Notes). The
sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%. The 4.875% Notes pay a fixed rate
of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a
redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the
indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our
obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and
future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including
limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and
other covenants. We were in compliance with these covenants as of December 31, 2014. There are no restrictive
covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and
distributions to shareholders or current ratios.

Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement, replacing the Amended and
Restated Credit Agreement of June 2010, which expired on June 21, 2014. Borrowings under the Credit Agreement
are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general
corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2014 or
2013, however $5.0 million was utilized for domestic standby letters of credit that reduced our borrowing
availability. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the
borrowing rate would have been 1.5% at December 31, 2014.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things.
These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our
ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or
consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and
covenants as of December 31, 2014.

Maturities of long-term debt at December 31, 2014 are as follows: 2015 - $0.3 million; 2016 - $0.3 million; 2017 -
$0.3 million; 2018 - $0.3 million; 2019 - $0.2 million; thereafter - $436.2 million.

6. INCOME TAXES

The U.S. and international components of income before taxes are as follows (in millions):

U.S.
International
Income before taxes

Year Ended December 31,

2014

2013

2012

30.6 $
101.0
131.6 $

5.7 $

106.7
112.4 $

110.6
119.3
229.9

The provision for income taxes consists of the following (in millions):

Current tax expense (benefit):
U.S. Federal
State

International
Current tax expense
Deferred tax (benefit) expense:

U.S. Federal
State
International

Deferred tax benefit
Non-current tax expense (benefit)
Provision for income taxes

Year Ended December 31,
2013

2012

2014

9.6 $
3.8
35.6
49.0

1.5
(0.2)
(7.3)
(6.0)
(0.3)
42.7 $

(5.0) $
0.6
38.3
33.9

4.8
(0.1)
(9.4)
(4.7)
5.4
34.6 $

34.4
4.1
37.3
75.8

(3.1)
(0.9)
(6.3)
(10.3)
(1.1)
64.4

The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:

U.S. statutory tax rate
Impact of foreign operations
Research tax credits
Nontaxable subsidies
Tax settlements and changes to unrecognized tax benefits
Fines and penalties
Contingent consideration
Other
Provision for income taxes

Year Ended December 31,
2013

2012

2014

35%
(4)
(3)
(2)
(1)
3
—
4
32%

35%
(6)
(6)
(2)
5
1
(1)
5
31%

35%
(3)
—
(1)
—
—
(2)
(1)
28%

The effective tax rates for 2014 and 2013 are approximately the same. The effective tax rate for 2014 includes a
lower tax benefit of research tax credits because the effective tax rate for 2013 included a significant tax benefit
related to the 2012 U.S. federal research credit, which was retroactively reinstated on January 2, 2013. The
additional tax benefit of research credits in 2013 was offset by an increase in tax liabilities for unrecognized tax
benefits and audit settlements in our foreign jurisdictions.

Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the
carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. Significant components of deferred tax assets and liabilities are as follows (in millions):

Deferred tax assets:

Bad debt, inventory and warranty accruals
Legal reserves
Other post-employment benefits, vacation and other reserves
Tax credit and net operating loss carryforwards
Other
Total gross deferred tax assets
Valuation allowance

Total deferred tax assets
Deferred tax liabilities:

Property and equipment
Investments and intangible assets

Total deferred tax liabilities

Net deferred tax liabilities

December 31,

2014

2013

25.3 $
2.0
23.6
60.5
28.4
139.8
(58.6)
81.2

12.9
158.2
171.1
(89.9) $

27.5
12.0
22.2
62.3
19.0
143.0
(64.0)
79.0

17.2
147.0
164.2
(85.2)

At December 31, 2014, Bio-Rad’s international subsidiaries had combined net operating loss carryforwards of
$106.8 million. Of these loss carryforwards, $105.6 million have no expiration date. We believe that it is more
likely than not that the benefit from most of these net operating loss carryforwards will not be realized. We have
provided a valuation allowance of $23.6 million relating to these net operating loss carryforwards.

At December 31, 2014, Bio-Rad had U.S. Federal net operating loss carryforwards of approximately $10 million as
a result of acquisitions. These carryforwards are subject to limitation on their utilization and will expire between
2018 and 2034. At December 31, 2014, Bio-Rad had U.S. Federal research tax credit carryforwards of $5.3 million,
$1.9 million of which are subject to limitations on their utilization.

At December 31, 2014, Bio-Rad had approximately $53 million of California net operating loss carryforwards
related to the acquisition of QuantaLife. We believe that it is more likely than not that the benefit from these net
operating loss carryforwards will not be realized and have recorded a full valuation allowance against these losses.
At December 31, 2014, Bio-Rad had a deferred tax asset of $20.2 million relating to California research tax credit
carryforwards, including $2.0 million from the acquisition of QuantaLife, which may be carried forward
indefinitely. Based on our judgment and consistent with prior years, we have recorded a full valuation allowance
against the deferred tax asset.

We believe that it is more likely than not that certain of these deferred tax assets described above will not be
realized in the foreseeable future. If or when recognized, the tax benefits relating to any reversal of the valuation
allowance on deferred tax assets at December 31, 2014 will be recognized as a reduction of income tax expense.

The tax years subject to examination by tax authorities in major jurisdictions that Bio-Rad operates in include the
years 2009 and forward for the U.S., and the years 2008 and forward for certain foreign jurisdictions, including
France, Switzerland and Germany.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):

Unrecognized tax benefits – January 1

Additions to tax positions related to prior years
Reductions to tax positions related to prior years
Additions to tax positions related to the current year
Settlements
Lapse of statute of limitations
Acquisitions
Currency translation
Unrecognized tax benefits – December 31

2014

2013

2012

16.2 $

12.6 $

1.7
(1.5)
1.6
(0.4)
(2.6)
—
(0.8)

4.7
(0.8)
2.0
(0.3)
(1.7)
—
(0.3)

14.2 $

16.2 $

11.3

1.3
(0.8)
1.6
—
(3.0)
2.2
—

12.6

Substantially all our unrecognized tax benefits at December 31, 2014, 2013 and 2012 would affect the effective tax
rate if recognized.

Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.
Related to the unrecognized tax benefits noted above, Bio-Rad has accrued interest of $3.8 million, $3.4 million and
$1.9 million as of December 31, 2014, 2013 and 2012, respectively.

At December 31, 2014, we believe that it is reasonably possible that $6.8 million of our unrecognized tax benefits
may be recognized by the end of 2015 as a result of statute lapses. These benefits are related to uncertainty
regarding sustainability of certain deductions and credits for tax years that remain subject to examination by the
relevant tax authorities.

In general, it is our practice and intention to reinvest the earnings of our non-U.S. subsidiaries in their operations.
As of December 31, 2014, Bio-Rad had not made a provision for U.S. or additional foreign withholding taxes on
approximately $512 million of the excess of the amount for financial reporting over the tax basis of investments in
foreign subsidiaries that are essentially permanent in duration. Generally, such amounts become subject to U.S.
taxation upon remittance of dividends and under certain other circumstances. If these earnings were repatriated to
the U.S., the deferred tax liability associated with these temporary differences would be approximately
$106 million.

STOCKHOLDERS' EQUITY

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock
(Class B). Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all
respects except as follows. Class A has limited voting rights. Each share of Class A is entitled to one tenth of a
vote on most matters, and each share of Class B is entitled to one vote. Additionally, Class A stockholders are
entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors.
Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash
dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B
shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder. The
founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock. As a result, the
Schwartz family is able to exercise significant influence over Bio-Rad.

Changes to Bio-Rad's issued common stock shares are as follows (in thousands):

Class A Shares

Class B Shares

Balance at January 1, 2012

B to A conversions

Issuance of common stock

23,020

253

Balance at December 31, 2012

23,333

B to A conversions

Issuance of common stock

269

Balance at December 31, 2013

23,681

B to A conversions

Issuance of common stock

286

5,165

(59)

5,150

(80)

5,097

(5)

Balance at December 31, 2014

23,972

5,099

Treasury Shares

The Board of Directors has authorized the repurchase of up to $18.0 million of Bio-Rad's common stock, of which
$3.3 million has yet to be repurchased in the open market as of December 31, 2014. The Amended and Restated
Credit Agreement (Credit Agreement) limits our ability to repurchase our stock. In accordance with the terms of
awards under the 2007 Incentive Award Plan, in June 2012, we withheld 122 shares of our Class A common stock
and 917 shares of our Class B common stock to satisfy the minimum statutory tax obligations due upon the vesting
of restricted stock of certain of our employees, which is considered a repurchase of our stock. All of the restricted
stock vested as of December 31, 2013, and therefore we do not anticipate any repurchasing of shares for this
purpose. We had no other repurchases of our stock during 2014 or 2013.

ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated
Statements of Changes in Stockholders' Equity consists of the following components (in millions):

Foreign
currency
translation
adjustments

Foreign other
post-
employment
benefits
adjustments

Net
unrealized
holding
gains on
available-
for-sale
investments

Bio-Rad
Accumulated
other
comprehensive
income

Total
Accumulated
other
comprehensive
income

Non-
controlling
interests

172.9 $

(8.1) $

109.7 $

274.5 $

(0.2) $

274.3

16.7

(0.7)

78.3

94.3

(0.2)

—

16.5

0.7

—

0.3

(28.9)

0.8

(28.9)

49.7

66.2

—

0.2

—

0.2

94.3

1.0

(28.9)

66.4

189.4 $

(8.1) $

159.4 $

340.7 $

— $

340.7

(117.0)

(11.4)

7.3

(121.1)

(1.2)

—

0.7

2.5

—

(2.7)

(0.5)

(0.2)

(118.2)

(8.2)

4.6

(121.8)

—

(121.1)

(0.5)

(0.2)

(121.8)

71.2 $

(16.3) $

164.0 $

218.9 $

— $

218.9

Balances as of January 1,
2013
Other comprehensive income

(loss), before
reclassifications

Amounts reclassified from

Accumulated other
comprehensive income

Income Tax Effects

Other comprehensive

income, net of income
taxes

Balances as of December 31,

2013

Other comprehensive (loss)

income, before
reclassifications

Amounts reclassified from

Accumulated other
comprehensive income

Income Tax Effects

Other comprehensive (loss)
income, net of income
taxes

Balances as of December 31,

2014

The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of
Income, with presentation location, were as follows:

Income before taxes impact (in millions):

Components of Comprehensive income
Liquidation of entity
Amortization of foreign other post-employment
benefit items
Net holding losses on available for sale investments

December 31,

2014

2013

1.2 $

0.2

(0.7) $
— $

(0.7)
(0.3)

$
$

Location
Cost of goods sold
Selling, general and administrative
expense
Other (income) expense, net

Reclassification adjustments are calculated using the specific identification method.

9. SHARE-BASED COMPENSATION/STOCK OPTION AND PURCHASE PLANS

Description of Share-Based Compensation Plans

Stock Option and Award Plans
We have three stock option plans for officers and certain other employees: the 1994 Stock Option Plan (1994 Plan);
the 2003 Stock Option Plan (2003 Plan); and the 2007 Incentive Award Plan (2007 Plan). The 1994 Plan and 2003
Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan
authorizes the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other
types of equity awards to employees. We no longer grant stock option grants under the 1994 Plan or 2003 Plan.
Since 2007, all share-based compensation grants have been from the 2007 Plan. A total of 2,250,360 shares have
been reserved for issuance of equity awards under the 2007 Plan and may be of either Class A or Class B common
stock as specified within the plan. At December 31, 2014, there were 957,053 shares available to be granted in the
future.

Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the
underlying common stock on the date of grant. Generally, options granted have a term of 10 years and vest in
increments of 20% per year over a five-year period on the yearly anniversary date of the grant. Stock awards issued
under the 2007 Plan generally vest in increments of 20% per year over a five-year period on the yearly anniversary
date of the grant.

Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10%
of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock. The
employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the
last business day of each calendar quarter.

The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an
“employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the
“Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an
“employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 600,000 shares of
Class A common stock under the 2011 ESPP.

Share-Based Compensation Expense

Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases,
restricted stock and restricted stock unit awards. Share-based compensation expense is allocated to Cost of goods
sold, Research and development expense, and Selling, general and administrative expense in the Consolidated
Statements of Income.

For 2014, 2013 and 2012, we recognized share-based compensation expense of $14.9 million, $13.7 million and
$13.2 million, respectively. We did not capitalize any share-based compensation expense in inventory.

For options and awards, we amortize the fair value on a straight-line basis. All stock compensation awards are
amortized over the requisite service periods of the awards, which are generally the vesting periods.

Stock Options
The following table summarizes stock option activity:

Outstanding, January 1, 2012

Granted
Exercised
Forfeited/expired

Outstanding, December 31, 2012

Granted
Exercised
Forfeited/expired

Outstanding, December 31, 2013

Granted
Exercised
Forfeited/expired

Outstanding, December 31, 2014
Vested and expected to vest,

December 31, 2014

Exercisable, December 31, 2014

Weighted-
Average
Exercise Price
63.50
107.32
44.66
87.78
70.83
117.67
54.16
91.32
78.72
119.71
63.66
100.29
84.50

$
$
$
$
$
$
$
$
$
$
$
$
$

888,750
55,250
(181,707)
(15,000)
747,293
55,050
(159,450)
(13,250)
629,643
54,000
(91,387)
(10,450)
581,806

565,246
428,726

$
$

83.61
74.62

Weighted-
Average
Remaining
Contractual
Term (in
years)

Aggregate
Intrinsic
Value
(in millions)

4.40

4.28
2.96

$
$

21.0

20.9
19.7

Intrinsic value for stock options is defined as the difference between the current market value and the grant price.
The total intrinsic value on the date of exercise of stock options exercised during 2014, 2013 and 2012 was
approximately $5 million, $11 million and $11 million, respectively. The total grant date fair value of options
vested during 2014, 2013 and 2012 was $2.1 million, $2.2 million and $2.3 million, respectively.

Cash received from stock options exercised during 2014, 2013 and 2012 was $5.8 million, $4.1 million and
$3.4 million, respectively. The actual tax benefit realized for the tax deductions from stock options exercised
totaled $5.3 million, $6.6 million and $6.5 million in 2014, 2013 and 2012, respectively.

As of December 31, 2014, there was $6.2 million of total unrecognized compensation cost from stock options. This
amount is expected to be recognized in the future over a weighted-average period of approximately 3 years.

The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing
model with the following weighted-average assumptions:

Expected volatility
Risk-free interest rate
Expected life (in years)
Expected dividend
Weighted-average fair value of options granted

Year Ended December 31,
2013

2012

2014

25%
2.35%
8.7
—
43.96

28%
2.65%
8.9
—
47.25

30%
1.53%
9.0
—
41.82

Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s
expected life. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.
The expected life represents the number of years that we estimate, based primarily on historical experience, that the
options will be outstanding prior to exercise. We do not anticipate paying any cash dividends in the future and
therefore use an expected dividend yield of zero.

Restricted Stock and Restricted Stock Units
Under the 2007 Plan, restricted stock was last granted in 2008. Restricted stock units, which are rights to receive
shares of company stock, were granted from 2007 through 2014 under the 2007 Plan. The fair value of each
restricted stock share and restricted stock unit is the market value as determined by the closing price of the stock on
the day of grant.

The following table summarizes restricted stock and restricted stock unit activity:

Restricted Stock &
Restricted Stock
Units

Weighted-
Average
Grant-Date
Fair Value

Weighted-Average
Remaining
Contractual Term
(in years)

Aggregate
Intrinsic Value
(in millions)

Outstanding, January 1, 2012

Granted
Vested
Forfeited

Outstanding, December 31, 2012

Granted
Vested
Forfeited

Outstanding, December 31, 2013

Granted
Vested
Forfeited

Outstanding, December 31, 2014

338,991
138,840
(100,590)
(15,783)
361,458
144,445
(104,883)
(25,590)
375,430
145,695
(107,557)
(36,203)
377,365

$
$
$
$
$
$
$
$
$
$
$
$
$

87.81
107.32
84.64
88.81
96.15
117.09
91.76
95.97
105.44
119.56
98.52
108.17
112.60

3.54

45.5

The total grant date fair value of restricted stock and restricted stock units in 2014, 2013 and 2012 was $10.6
million, $9.6 million and $8.5 million, respectively. As of December 31, 2014, there was approximately $33.9
million of total unrecognized compensation cost related to restricted stock units. This amount is expected to be
recognized over a remaining weighted-average period of approximately 4 years.

Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP and the 1988 ESPP was estimated using a
Black-Scholes model with the following weighted-average assumptions:

Expected volatility
Risk-free interest rate
Expected life (in years)
Expected dividend
Weighted-average fair value

of purchase rights

Year Ended December 31,
2013

2012

2014

15%

0.04%
0.25
—

19%
0.05%
0.25
—

27%
0.07%
0.25
—

$21.88

$21.76

$20.70

The major assumptions are primarily based on historical data. Volatility is based on the historical volatilities of our
common stock for a period equal to the expected life of the purchase rights. The risk-free interest rate is based on
the U.S. Treasury yield curve in effect at the time of the grant. We do not anticipate paying any cash dividends in
the future and therefore use an expected dividend yield of zero.

We sold 102,222 shares for $10.2 million, 103,669 shares for $10.0 million and 107,749 shares for $9.2 million
under the 2011 ESPP to employees in 2014, 2013 and 2012, respectively. At December 31, 2014, 286,360 shares
remain authorized and available for issuance under the 2011 ESPP.

We currently issue new shares to satisfy stock option exercises, restricted stock issuances and ESPP stock
purchases.

10. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):

Year Ended December 31,
2013

2014

2012

Interest and investment income
Net realized losses (gains) on investments
Other-than-temporary impairment losses on investments
Losses (gains) on disposal of property, plant and equipment
Miscellaneous other (income) expense items, net

(13.5) $
—
0.4
0.4
(0.3)

(13.4) $
0.3
0.3
0.5
(0.5)

(11.4)
(8.7)
1.0
(3.8)
1.0

Other (income) expense, net

(13.0) $

(12.8) $

(21.9)

Other-than-temporary impairment losses on investments were recorded in 2014, 2013 and 2012 on certain of our
available-for-sale investments and a certain equity investment in light of the continuing declines in their market
prices at that time, primarily associated with our investment in a sovereign nation with large deficits and our
decision to sell holdings in a particular adviser account.

In December 2012, we sold a building for $6.4 million in our Clinical Diagnostics segment that was associated with
a 1999 acquisition. We recognized a gain on the sale of $4.3 million and a portion of goodwill recorded in a 1999
acquisition was written off of $1.0 million.

11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income including noncontrolling interests to net cash provided by operating
activities is as follows (in millions):

Net income including noncontrolling interests
Adjustments to reconcile net income including
noncontrolling interests to net cash provided
by operating activities (net of effects of
acquisitions):

Depreciation and amortization
Share-based compensation
Losses (gains) on dispositions of securities
Losses (gains) on dispositions of fixed assets
Excess tax benefits from share-based
compensation
Changes in fair value of contingent
consideration
Decrease (increase) in accounts receivable, net
Decrease (increase) in inventories, net
Increase in other current assets
(Decrease) increase in accounts payable

and other current liabilities

Increase (decrease) in income taxes payable
Decrease in deferred income taxes
Write-off of goodwill
Net increase/decrease in other long-term
liabilities/assets

Year Ended December 31,

2014

2013

2012

88.8 $

77.8

165.5

149.9
14.9
0.3
0.4

(1.3)

(1.4)
11.1
5.8
(5.7)

(9.9)
20.4
(6.3)
—

6.3

147.2
13.7
0.6
0.5

(2.7)

(5.8)
(24.2)
(39.7)
(4.2)

33.2
(38.0)
(4.0)
—

14.7

(1)

130.4
13.2
(7.6)
(4.8)

(2.9)

(16.1)
4.4
(13.9) (1)
(5.6)

19.0
(18.0)
(10.3)
1.0

12.2

Net cash provided by operating activities

273.3 $

169.1

(1) $

266.5 (1)

Non-cash investing activities:
Purchased intangible assets
Purchased marketable securities and
investments
$
(1) Amounts revised, see Note 1 "Correction of Immaterial Errors"

0.2 $

— $

12.0

0.4

0.5

1.6

12. COMMITMENTS AND CONTINGENT LIABILITIES

Rents and Leases

Net rental expense under operating leases was $46.9 million, $45.5 million and $41.4 million in 2014, 2013 and
2012, respectively. Leases are principally for facilities and automobiles.

Annual future minimum lease payments at December 31, 2014 under operating leases are as follows: 2015 -
$39.3 million; 2016 - $33.6 million; 2017 - $25.7 million; 2018 - $18.5 million; and 2019 and beyond -
$36.7 million.

Deferred Profit Sharing Retirement Plan

We have a profit sharing plan covering substantially all U.S. employees. Contributions are made at the discretion of
the Board of Directors. Bio-Rad has no liability other than for the current year’s contribution. Contribution
expense was $13.7 million, $13.5 million and $12.1 million in 2014, 2013 and 2012, respectively.